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ABSTRACT OF THE DISSERTATION
Sequence analysis methods for the design of cancer vaccines that target tumor-specific
mutant antigens (neoantigens)
by
Jasreet Hundal
Doctor of Philosophy in Biology and Biomedical Sciences
Human & Statistical Genetics
Washington University in St. Louis, 2018
Professor Elaine R Mardis, Chair
Professor Malachi Griffith, Co-Chair

The human adaptive immune system is programmed to distinguish between self and non-self
proteins and if trained to recognize markers unique to a cancer, it may be possible to
stimulate the selective destruction of cancer cells. Therapeutic cancer vaccines aim to boost
the immune system by selectively increasing the population of T cells specifically targeted to
the tumor-unique antigens, thereby initiating cancer cell death.. In the past, this approach has
primarily focused on targeted selection of ‘shared’ tumor antigens, found across many
patients. The advent of massively parallel sequencing and specialized analytical approaches
has enabled more efficient characterization of tumor-specific mutant antigens, or neoantigens.
Specifically, methods to predict which tumor-specific mutant peptides (neoantigens) can
elicit anti-tumor T cell recognition

improve predictions of immune checkpoint therapy

response and identify one or more neoantigens as targets for personalized vaccines. Selecting
the best/most immunogenic neoantigens from a large number of mutations is an important
challenge, in particular in cancers with a high mutational load, such as melanomas and
xi

smoker-associated lung cancers. To address such a challenging task, Chapter 1 of this thesis
describes a genome-guided in silico approach to identifying tumor neoantigens that integrates
tumor mutation and expression data (DNA- and RNA-Seq). The cancer vaccine design
process, from read alignment to variant calling and neoantigen prediction, typically assumes
that the genotype of the Human Reference Genome sequence surrounding each somatic
variant is representative of the patient’s genome sequence, and does not account for the effect
of nearby variants (somatic or germline) in the neoantigenic peptide sequence. Because the
accuracy of neoantigen identification has important implications for many clinical trials and
studies of basic cancer immunology, Chapter 2 describes and supports the need for patientspecific inclusion of proximal variants to address this previously oversimplified assumption
in the identification of neoantigens. The method of neoantigen identification described in
Chapter 1 was subsequently extended (Chapter 3) and improved by the addition of a modular
workflow that aids in each component of the neoantigen prediction process from neoantigen
identification, prioritization, data visualization, and DNA vaccine design. These chapters
describe massively parallel sequence analysis methods that will help in the identification and
subsequent refinement of patient-specific antigens for use in personalized immunotherapy.

xii

Chapter 1: Introduction & Background
1.1 Introduction
After the landmark discovery of the double helix structure of deoxyribonucleic acid (DNA) in
1953 by Watson and Crick, coupled with several advances in molecular biology techniques,
specifically the dideoxynucleotide sequencing techniques of Sanger, the completion of the
human reference sequence in 2004, and the development of basic computational DNA
analysis and annotation software, heralded a new era for disease research1. ‘Finishing’ the
first human reference genome sequence provided a new roadmap to understanding where
genes in the genome were located and organized on chromosomes. A few years after the
Human Genome Reference sequence was announced, a new paradigm shift occurred in the
process of DNA sequencing data production. The new DNA sequencing instruments and
methods, known collectively as massively parallel sequencing (MPS), could process millions
of sequence reads in parallel in a single instrument run compared to previous Sanger
methods, and thereby significantly reduced the time, resources and costs to generate genome
sequencing data. These techniques were also called ‘next generation’ sequencing
technologies as they truly spurred a new direction to producing genomic data.2

1.2 Massively Parallel Sequencing (MPS) technologies and
analysis
Several different technologies and companies emerged around the same timeframe, with
different approaches to next generation sequencing3. Some of the early commercial
contributors were Roche/454, Applied Biosystems SOLiD and Illumina, that differed based
1

on the sequencing chemistry used- pyrosequencing for Roche/454, ligation-based sequencing
for SOLiD and polymerase-based sequencing-by-synthesis for Illumina. Amongst these,
Illumina emerged as a market leader in terms of maintaining a reasonable cost of sequencing
per Gb of data as well as the accuracy and applicability of the data generated. Currently,
Illumina’s platform is the most widely used in the field.

1.2.1 Steps to generate MPS data
There are three main steps that are involved in generating MPS data. The first and foremost
step is library production. This involves shearing and fragmenting genomic DNA,
enzymatically polishing the fragment ends, and ligating known sequence adapters onto the
fragment ends. These adapters may also carry bar coded DNA identifiers or indexes to permit
downstream pooling of samples. The next step involves attaching these adapter-ligated
library sequences onto a solid surface with complementary adapter sequences, and
enzymatically amplifying the fragments. Fragment amplification is needed to provide
sufficient signal during the sequencing reaction for on-instrument detection. Similarly,
libraries for generating RNA-Seq data also can be prepared for MPS, first by conversion of
the RNA to DNA using reverse transcriptase, followed by adapter ligation and surface
amplification. The data resulting from RNA-Seq can be analyzed to determine digital
expression values for genes in a given tissue or tumor. The last step is sequence data
generation by reading the signals produced from the stepwise sequencing process that occurs
at each amplified fragment population. This process involves detecting the identity of each
nucleotide base that is added by DNA polymerase onto the fragments in each amplified
library fragment cluster, obtained from differential label detection in certain instruments or
by the sequential addition of each nucleotide reagent being coupled with a subsequent
detection step that follows each nucleotide addition. Because this sequencing process takes
2

place on the solid support, for hundreds of millions to billions of fragment clusters being
sequenced in parallel, the technology is called ‘massively parallel’ sequencing. The read
length for most commonly used MPS technologies is relatively shorter (100-300bp) than
traditional Sanger sequencing read lengths (800bp). This fact, coupled with the high
throughput approach to sequencing enabled by MPS, requires analysis of the resulting reads
by in silico alignment to a fixed reference genome, followed by variant detection. In turn, the
requisite sampling level or “coverage” needed to sequence genomes and obtain high
confidence variant calling is nearly triple that of Sanger sequencing coverage levels (30-fold
or higher coverage by MPS versus 8-10 fold coverage by Sanger). Additionally, the more
compute-intensive nature of analyzing MPS data sets for genomes as large as the human
(3Bbp), means that these large data sets require carefully constructed and validated analytical
pipelines.

MPS can be used to either sequence the entire genome (whole genome sequencing or WGS),
or there are methods to select out genomic content from a whole genome library, such as the
exons of known protein-coding genes (“exome”) or a smaller number of selected genes or
regions (“panel”). This is typically accomplished by an approach called “hybridization
capture” sequencing or “exome” sequencing (in case of all protein coding genes), whereby
synthetic probes designed to hybridize the exon sequences of protein coding genes are
designed with covalently attached biotin molecules. By mixing such probes with the library
fragments from a whole genome library under appropriate conditions, hybrids form between
the synthetic probes and their cognate sequences in the library. These hybrids are
subsequently captured by mixture with streptavidin-labeled magnetic beads, due to the
binding of biotin by streptavidin, and subsequently the hybrids are isolated by applying a
magnetic pull-down to isolate them from the remaining mixture. After isolation, the captured
3

library fragments are denatured from the synthetic probes and sequenced by MPS. Since
human exome sequencing targets only the exons, which make up about 1.5% of the genome,
the attendant data production is less expensive, the reads are more readily interpreted for
variants, and the depth of coverage obtained can be higher and therefore more sensitive than
compared to whole genome sequencing.

1.2.2 Analysis of MPS data
The sequence read alignment step is most often preceded by quality control of raw
sequencing data and data preprocessing steps such as trimming of adapter sequence data from
the reads. The quality control procedure can inform about any GC bias in the sequencing
experiment by analyzing the GC content distribution, as well as any inconsistencies in the
experiment by determining the read length distribution.

While smaller, less complex genomes (viral or bacterial) can be assembled from the resulting
short read MPS data using specific assembly algorithms, larger complex genomes like the
human require alignment of short sequencing reads to the reference genome as a first step
toward data analysis. In genomes such as human, mapping the reads to the reference genome
is further complicated by not-yet-completed gaps in the reference genome or by differences
between the reference and the genome being studied, including structural variants
(chromosomal inversions, deletions, and translocations). Additionally, 48% of the human
genome consists of repetitive elements that complicate accurate mapping of short reads due
to multiple mapping likelihood at many regions in the genome.

The post alignment processing involves data recalibration to mark and/or remove duplicates,
and recalculation of quality scores after adjusting for local misalignments. Duplicate
4

sequencing reads may arise due to preferential enzymatic amplification of DNA fragments by
the polymerase, especially when there are differences in the length of library fragments
(shorter fragments are amplified preferentially) or differences in G-C content (more skewed
A-T/G-C ratios amplify poorly). Such duplicates are reduced to a single read representative
by de-duplicating software to avoid misrepresentation of copy number altered regions or to
propagate PCR errors. To identify focal structural variants i.e. small insertions or deletions,
the read data require a realignment and base quality score recalibration (BQSR) process to
enhance their detection by variant calling software programs.

After mapping and post-processing of the aligned reads to the reference genome, variant
calling algorithms identify mutations in the sequenced DNA compared to the reference. This
includes detection of several different types of variants such as single nucleotide variants
(SNVs), focal insertions and deletions (indels), and copy number variants.

One of the major prerequisites for successful detection of high quality variants is adequate
sequence read data coverage of the genome or exome, which ensures sufficient depth on a
given region of interest has been achieved to give statistical confidence of any variant
identified therein. Also, filtering of discordant reads, such as those with multiple mismatches
above a set threshold avoids sequencing errors being called as variants. Finally, variants
called in aligned reads due to known false positivity contributors are often removed using
statistical filters, such as variants found at the ends of reads where data quality is generally
lower or variants called with reads only originating from single read orientation.

The variant list is then annotated to determine the protein level effect of the peptide changes
and to assess the functional significance of the predicted variants. The pathogenicity of
5

variants are then evaluated. Some commonly used tools to annotate and predict functional
impact include Variant Effect Predictor (VEP)4,5, SIFT6,7, CHASM8, PolyPhen-29,
MutationAssessor10, and ParsSNP4911. The mutation calls can be classified into different
types depending on their effect on the resulting protein sequence such as - a) Missense
(nonsynonymous) mutation, where a single amino acid changes to another amino acid b)
Nonsense mutation: where the point mutation changes an amino acid to a STOP codon
resulting in premature termination of translation c) Silent (synonymous) mutation: where the
resulting mutation does not change an amino acid d) Frameshift mutation: these include
insertion or deletion of a number of bases such that the frame of translation changes, leading
to a completely new amino acid sequence and/or introducing a premature STOP codon, e)
stopgain mutation, which eliminates the wildtype stop codon, resulting in a longer protein
sequence. Furthermore, these mutations could either lead to “loss of function” of the protein
or “gain of function”, either of which may be equally important.

1.3 Cancer genome sequencing
1.3.1 Large scale tumor genome sequencing projects
As MPS technologies have attained widespread use and expanding application to multiple
experimental aspects of biomedical research, their application to cancer genome
characterization and discovery of new cancer genes in the research setting has been profound.

The first MPS-based cancer genome was sequenced and reported by Ley et al12 in 2008.
Single patient cancer genome sequencing studies such as this study also highlighted the
importance of sequencing the patient’s normal genome in addition to the tumor genome13, as
a means of distinguishing inherited (“germline”) alterations from those acquired in and
6

thereby specific to, the cancer genome (“somatic”). These initial small studies were
accomplished by WGS and were quite expensive at the time, but as the cost of generating
MPS data decreased, large-scale projects to discover and catalogue cancers were initiated and
resulted in data generation and analysis from thousands of adult and pediatric cancers. For
example, large scale sequencing efforts have been completed by several international
consortia, such as The Cancer Genome Atlas (TCGA)14, International Cancer Genome
Consortium (ICGC)15, Pediatric Cancer Genome Project (PCGP) and Pan Cancer Analysis of
Whole Genomes (PCAWG). Due to the advances in MPS technologies and analytical
approaches, it was possible to sequence and identify the full range of somatic alterations in
the genome, including single nucleotide variations, insertions and deletions, copy number
variations, and large genomic rearrangements such as translocations, inversions, and other
complex structural rearrangements16.

In addition to defining the genomic landscape of thousands of cancer genomes across many
disease types, these projects revealed the heterogeneity of mutational burden across cancer
types (Figure 1.1). A broad spectrum of mutational frequencies is observed between, for
example, carcinogen driven tumors such as tobacco smoking-associated lung cancers and
UV radiation-driven melanomas which show the highest mutational burden, versus
hematological tumors that have the lowest mutational load.

7

Figure 1.1 Mutational heterogeneity of cancer. Figure originally published in Lawrence et.
al.17 "Each dot corresponds to a tumor–normal pair, with vertical position indicating the
total frequency of somatic mutations in the exome. Tumor types are ordered by their median
somatic mutation frequency, with the lowest frequencies (left) found in hematological and
pediatric tumors, and the highest (right) in tumors induced by carcinogens such as tobacco
smoke and ultraviolet light. Mutation frequencies vary more than 1,000-fold between lowest
and highest across different cancers and also within several tumor types. The bottom panel
shows the relative proportions of the six different possible base-pair substitutions, as
indicated in the legend on the left." 17
Also, the large scale detailed analysis of the patient cohorts has led to findings about driver
genes, driver mutations and passenger mutations, including the identification of significantly
mutated genes (SMGs) occurring within specific tissue sites, as well as across multiple cancer
types. These characterizations of genetic alterations have helped in substantially advancing
our understanding of cancer genomes, especially as the data are integrated with RNAseq,
methylation and other omics data types produced concurrently.

By capturing even low abundance aberrations in clonal populations using MPS, these studies
have also highlighted that even individual tumor types can have substantial genomic
heterogeneity. It was found that even though there were SMGs seen across patient cohorts, at
an individual patient level, the patterns and combinations of mutations that led to
8

development of cancer were different. This complexity further underscored the need to
sequence each patient’s genome, due to the level of detail needed to discern and characterize
the individual disease.

1.3.2 Cancer genomics based treatments
Coincident with our ability to sequence cancer DNA has been the development of new
classes of cancer therapies that are developed to address specific cancer driver gene
alterations. Initially, these were therapies such as Imatinib that targeted the protein fusion
product of the BCR-ABL gene fusion, or Herceptin that targeted HER2 amplified breast
cancers, both of which are interpretable without the need for DNA sequencing. Over time due
to enhanced discovery offered by MPS-based analysis, we have now ascertained that cancer
genes can be mutated in different tissue sites, such as BRAF mutations in melanomas, lung
cancers, and brain cancers. This new realization has shifted diagnostic applications of MPS18
from single gene mutation testing (often accomplished by PCR and Sanger sequencing) to
multi-gene panel assays capable of surveying the many possible genes that may be mutated
and may offer treatment decision-supporting evidence to physicians. Gene panel testing is
also favored because it is cost effective and less time consuming to analyze the resulting data.
It also offers a high rate of sensitivity to detect mutations in tumor DNA, which often has
different amounts of normal cells interspersed that can decrease sensitivity, since it is
possible to achieve fairly high coverage (300-500x) at the regions of interest.

Due to unprecedented leaps in our understanding of cancer development powered by large
scale sequencing of cancer samples, genomics based treatments have allowed the field of
therapeutics move away from a ‘one size fits all’ approach to one that is more personalized to
9

the patient’s genome. Concurrently, advances in molecular drug development and targeted
therapies have enabled the transition of genomic assays into clinical use in patients with
cancer19.

Cancer genomics based assays have introduced a new era of molecular pathology and
personalized, or “precision” medicine. By interpreting genomic information in light of
targeted therapies, it is possible to identify additional cancer patients who might benefit.

An emerging use of cancer genomics data is in predicting responses from new classes of
cancer drugs known broadly as immunotherapy or immune checkpoint blockade therapy. In
particular, cancer patients who have responses to immune checkpoint blockade therapies have
been characterized by MPS as having an elevated mutational load or tumor mutation burden
(TMB). By coupling our understanding of the impact of high TMB, namely the encoding of
new protein sequences, that are unique to the cancer cells, with the potential impact on the
adaptive immune system that would identify these novel proteins/peptides as ‘non-self’, one
can predict that the response to immune checkpoint therapy is due to high numbers of tumorspecific mutant antigens (neoantigens) being presented to the immune system on these cancer
cells.

1.4 Cancer Immunotherapy
1.4.1 Tumor antigens
In the late twentieth century, the immune-focused therapies for cancer that were postulated
and tested did not deliver much clinical benefit, resulting in a diminution of enthusiasm for
such therapeutic approaches. These studies were based on the hypothesis that due to the
10

aberrations in the cancer genomes, unique peptides are presented on the cancer cells by the
major histocompatibility complex (MHC) molecules which are then recognized by the
Cytotoxic T lymphocytes (CTL)20,21. The altered peptides either could be normal
differentiation antigens or aberrantly expressed normal proteins that are overexpressed in
tumor cells versus the normal cells (tumor-associated antigens; TAAs), or those resulting
from either oncogenic viral proteins or mutations unique to the tumor (tumor-specific
antigens/neoantigens; TSAs).

Tumor Associated antigens arise from non-mutated self proteins and are aberrantly expressed
in tumor cells. One such type of self-differentiation antigens are the cancer–testis antigens
(CTAs) that are present in immune-privileged normal cells but also are selectively presented
to the immune system by tumor cells. These are not expressed in normal tissues except for
testis, fetal ovaries, and trophoblasts but are also expressed in varying tumor types22.
Melanoma Associated Antigen-1 (MAGE-1) was the first identified CTA which was
discovered in 199123 using autologous cytotoxic T lymphocytes and autologous tumor
mRNA. Another type of self-antigen is derived from non-mutated melanocyte lineagespecific antigens, which include Melan-A/MART-1, gp100, and tyrosinase. These antigens
usually have tissue specific expression and have been found to exhibit some level of enriched
expression in various cancers. Since TAAs are also present in the normal cells, there is a risk
of autoimmunity and the use of tumor-associated antigens as therapeutic targets can lead to
normal tissue destruction and toxicity.

TSAs are antigens arising from somatic changes in the tumor acquired during cancer
initiation and progression, resulting in unique peptide sequences and are not seen in the
normal cells. Since these peptides are specifically presented in the tumor cells, they are likely
11

to be less susceptible to mechanisms of immunological tolerance. Early works on mouse
models from the lab of Thierry Boon24 identified the first neoantigen resulting from a point
mutation in the P91A gene in a mutagenized mouse tumor. A few years later, Hans Schreiber
and colleagues25,26 demonstrated that tumor-specific mutations could result in immunogenic
tumor-specific neoantigens, and demonstrated in vivo tumor rejection based on T cells
targeting highly immunogenic, primary UV–induced mouse tumors. Another group
demonstrated an autologous antibody-based method to clone and identify different human
TSAs27. All of these efforts paved the way for harnessing the power of antigens - TAAs or
TSAs and showed an increasing evidence that the tumor antigenome was associated with a
combination of these antigens. However, historically targeting TSAs was more laborious and
challenging as the therapeutic strategies are specific to individual patients. As a result, the
focus was primarily on targeting the TAAs or shared antigens that are not tumor-specific but
expressed on large groups of cancers.

1.4.2 Pre-MPS identification of tumor antigens
Several approaches were developed to detect potential antigens that could be used for cancer
immunotherapy28,29. Traditionally, reverse-transcription-polymerase chain reaction (RT-PCR)
and real-time PCR (RQ-PCR) were used to detect expression of TAAs for a range of solid
and haematological malignancies but these assays were used to limited to tumor antigens
which had already been discovered. Another approach called Representational Difference
Analysis (RDA) was developed to identify the CTAs such as the MAGE family of antigens30.
Briefly, this technology uses subtractive hybridization to PCR-mediated kinetic enrichment to
detect the differences between RNA sequences from the normal tissue (driver) and a tumor
sample (tester).
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In 1995, Sahin et al27 developed a method of Serological analysis of tumor antigens by
Recombinant cDNA Expression cloning (SEREX). This method provided a base for high
throughput screening of several TAAs, and was used widely to screen for plethora of antigens
(> 2000) (http://www.licr.org/D_programs/d4a1i_SEREX.php) across different types of solid
tumors as well as haematological malignancies. One example is NY-ESO-1, which is
probably one of the most immunogenic CTAs discovered to date. It elicits specific CD4+ as
well as CD8+ T-cell mediated immune responses in patients with solid tumors. SEREX starts
with the construction of a cDNA library from freshly isolated tumor cells, which is expressed
recombinantly. Thereafter, recombinant proteins are transferred onto membranes and
screened with diluted serum of the same patient. TAAs are identified by their reactivity with
IgG antibodies present in the patient's serum. Though several antigens can be screened
together, one of the most laborious step in the SEREX approach is the construction
expression libraries. This approach also does not detect post-translational modifications.

Another approach known as serological proteome analysis (SERPA)31 combined proteomics
approaches for the purpose of separating proteins and the serological screening with human
serum antibodies. It involves using the proteomics workflow for an effective separation on 2DE gels for proteins that were extracted from primary tumors or cell lines, followed by an
identification by Mass Spectrometry (MS). Unlike SEREX, this does not depend on
recombinant expression of proteins, and thus can also screen for tumor specific posttranslational modifications of proteins.

Besides using the Mass Spectrometry (MS) based approaches, cDNA microarrays also have
been used to compare the differential expression of tumor antigens from normal tissues and
cancer tissues. Most of these approaches focused on the identification and validation of
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TAAs. Although there were attempts in the mid 1980’s to identify tumor-specific mutant
antigens (TSMAs) from cancers, these efforts were painstaking and not scalable using Sanger
sequencing approaches.

1.4.3 Neoantigens
Many early studies demonstrated the importance of TSMAs or neoantigens as significant
targets of antitumor immune responses32,33,34. However, screening for neoantigens before the
sequencing of the human genome and the advent of MPS, was a daunting task with very little
gain since it required the identification of mutations and HLA typing to be done for each
patient. Thus, much of the focus for cancer immunotherapy based treatments in the early
2000s was on targeting and evaluation of TAAs and CTAs, as described.

With the completion of the first sequence of the human reference genome in 2004, early
efforts to design PCR primers and amplify and Sanger sequence DNA from cancers to
identify somatic mutations emerged, making it clear that cancer cells, especially in some
tissue sites, carry multiple mutations in their genes. From these studies, a visionary
suggestion emerged35. In 2008, Allison and Vogelstein36 proposed that all cancers have
mutations that could form neoantigens by conducting an in silico analyses of exomesequencing data from breast and colorectal cancers. While the study lacked any experimental
validation of the predicted neoantigens, they profiled several mutations that were predicted to
form tumor-specific mutant antigens for CD8+ T cells, exhibiting the ability of the cancer
genome to form epitopes recognizable by the immune system due to accumulated genetic
changes.
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In 2012, two independent groups demonstrated neoantigen prediction approaches based on
MPS somatic variant identification, including how the identified variants, when considered in
the context of MHC binding affinity, could predict tumor specific neoantigens in murine
sarcoma models37,38. By using the resulting set of potential neoantigens to query T cell
reactivity, the predictions were validated. It was further demonstrated that these validated
neoantigens were the same epitopes recognized by anti-PD1 and anti-CTLA439 immune
checkpoint blockade therapies and that peptide vaccines comprised of the peptide
neoantigens provided either prophylactic or therapeutic efficacy. Several other studies have
also characterized neoantigens as being derived from somatically mutated genes40–43, and
have shown that they can be recognized by T-cells.
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Figure 1.2: An overview of self vs non-self paradigm for neoantigen vaccines: Figure
originally published in Houghton and Guevara-Patiño44 - “Initial studies demonstrated that
host CD8+ T cells respond to a self peptide presented by MHC-I molecules on tumor cells.
The wild-type self peptide ITDQVPFSV is unable to trigger an immune response against the
tumor cells either due to being a weak binder or being eliminated due to the process of selftolerance. The mutated peptide ITDQVPFSV results in a neoantigen which is highly stable
and activates the host T cells. Once the CD8+ T cells are activated, they are competent to
recognize and kill host tumor cells presenting the non-mutated self peptide.”
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These landmark studies by Matsushita et al37 and Castle et al38

introduced

“reverse

immunology approaches” for identification of neoantigens and opened new avenues to tailor
personalized treatments using TSMAs by exploiting the full mutanome of a patient. Briefly,
in these studies the analysis pipelines combined genomic, bioinformatic and immunological
methods45 to determine the set of most immunogenic neoantigens (Figure 1.2). Starting with
the set of somatic variants identified using MPS, the amino acid changes are translated, and
representative short peptides are generated that window through the variant amino acid, to
place it at locations from beginning to end in the peptide, and its ability to bind to the MHC is
determined using epitope prediction algorithms. The normal exome data are analyzed through
a specific algorithm to identify the HLA haplotypes used for this evaluation. The two most
critical components of this approach are the identification of high quality somatic mutations
using MPS data as well as accurate prediction of the peptide binding to the MHC alleles. As
mentioned in previous sections, depth of coverage by MPS sequencing reads from the tumor
is an important factor for detection of high confidence somatic variants. The coverage is also
needed to correctly infer clonality of the mutation, based on the reads that identify the variant
and their representation at the variant site of germline vs. mutant. This type of analysis is
needed to partition variants in the founder clone (those present in every cell) from those in
subclonal populations (not present in every cell, by inference). From an immunotherapy
perspective, targeting neoantigens that associate with the founder clone produces an immune
response that targets all cancer cells rather than only selected cells (i.e. those carrying
subclonal mutations/neoantigens). Another aspect that determines the immunogenicity of the
selected neoantigen is its ability to bind to the MHC molecule. Typical, peptides of lengths
8–11 amino acids bind to MHC Class I molecules that present them to cytotoxic CD8+ T
cells and peptides of longer lengths, typically between 11–30 amino acids, bind to MHC
Class II molecules and are presented to CD4+ T cells. Predicting the binding affinity of a
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large number of peptides arising from somatic mutations to the MHC alleles is onerous, and
therefore has now been streamlined by various computational pipelines.

1.4.4 Computational methods for peptide binding prediction to MHC
alleles
One critical component for the correct prediction of antigen binding to MHC alleles is
obtaining the high-resolution HLA allelotype of the patient. Traditionally, PCR and Sanger
sequencing-based clinical assays have been used to derive patient-specific HLA haplotypes.
More recently, several in silico based tools have been developed that can predict the correct
HLA haplotypes at up to a 99% accuracy for four-digit resolution46. These tools either use an
alignment-based approach or an assembly-based approach from MPS read data. Alignmentbased HLA typing softwares such as PolySolver47 and Optitype48 align the read to the
reference HLA sequences (genomic, exomic or transcriptomic) and use probabilistic
modeling to infer correct HLA types. Assembly-based approaches such as ATHLATES49 and
HLAminer50 involve de novo assembly of MPS read data into contigs which are then aligned
to the reference sequences of known HLA alleles to resolve the haplotypes.

Experimental screening of large numbers of predicted neoantigen candidates is an expensive
and time-consuming endeavor. As MPS technologies have become more widely used for
cancer immunogenomics evaluations51, computational methods to determine accurate binding
prediction of the peptides to the MHC molecules (Class I or Class II) have also evolved52.
Several computational tools of this type, including BIMAS53, SYFPEITHI54, and
RANKPEP55, rely on position-specific scoring matrices (PSSMs). These softwares make
predictions of MHC-peptide binding based on the position of amino acids in the putative neo18

peptide as it sits in the binding cleft of the protein, such as at the anchor position, unusual
anchor position, and auxiliary anchor position. The binding potential of different peptides is
based on identification of allele-specific motifs and by taking into account the positions of the
amino acids - optimally preferred positions of amino acids scored higher over the undesirably
placed amino acids in calculating the binding affinity.

After the widespread adoption of MPS, the number of MHC alleles (specifically HLA alleles)
that were identified also increased exponentially, and it became necessary to improve MHC
binding prediction methods. One major shortcoming of the PSSM based approaches was the
inability to correctly account for the interrelationships between different MHC cleft binding
positions. This was overcome by using more complex, machine learning-based approaches to
establish models for the different types of binding site interactions, and thereby determine
patterns of binding based on existing datasets. These machine learning-based methods are
broadly divided as follows:
a) Artificial neural networks (ANN): These methods are trained using a set of
experimentally derived binding affinity measurements for different class I and II
HLA haplotypes. One of the first software programs developed using ANN-based
modeling was NetMHC56,57. The accuracy of this method largely depends on the
quality and size of the training set, and hence it is more accurate for predicting MHCpeptide binding potential for the more common MHC alleles due to the relative
abundance of binding data for common haplotypes. Since rare HLA alleles are not as
well supported by experimental binding data, more accurate algorithms were
developed to calculate the peptide binding affinity potential to such alleles.
NetMHCpan57,58 and Pickpocket59 are two such pan-specific algorithms that were
trained by expanding the original training set to include data from other species, as
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well as extrapolating the affinities for rare alleles from known binding affinities.
Incorporating these additional parameters subsequently led to improved accuracy for
rare MHC alleles. Another ANN-based approach, applied in NetMHCCons60,
combines multiple tools to obtain more reliable binding affinity predictions and uses
consensus to compensate for the strengths and weaknesses of different algorithms.
Further improvements to neural network-based methods have resulted in tools such as
MHCflurry61 and MHCnuggets62.

b) Stabilized Matrix Method (SMM): These methods use protein position-weight
matrices to model the binding process. Examples include SMM63 and SMMPMBEC64
that use quantitative matrices not only for predicting binding of peptide to MHC class
I molecules, but also for predicting both the transport of the peptide by transporter
associated with antigen processing (TAP), and proteasomal cleavage of protein
sequence.
Though most of the efforts have been focused on developing methods for binding predictions
to MHC Class I molecules, some of these softwares such as NetMHCIIpan65 and
MHCnuggets62 , extend support for Class II predictions as well.

Once a list of strong binding peptide candidates is determined using the aforementioned
methods, the peptides are validated in vitro to determine their binding potential and/or their T
cell based immune response using different assays. These include MHC Peptide binding
assays that assess peptides based on their competitive binding to the MHC molecules,
ELISPOT/ELISA that measures IFNγ production, flow cytometry-based Peptide–MHC
tetramer/dextramer assays, or combinations of any of these.
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The selected neoantigen peptides could be further employed to study different aspects of
cancer immunology and immunotherapy. One type of cancer immunotherapy, called
‘immune checkpoint blockade’ acts by removing immune suppression by binding to cell
surface markers that induce T cell exhaustion. Several groups have studied the correlation
between

tumor mutation burden (TMB) or neoantigen load as a predictor of immune

checkpoint blockade response likelihood66,67, and have shown a strong association between
somatic mutation burden and clinical response in patients treated with anti-CTLA4 or antiPD1. While checkpoint blockade therapies predominately provide a tumor-specific immune
response, there could be often adverse reactions because these therapies target native immune
molecules such as CTLA-4, PD-1 and PD-L1. Another type of immunotherapy-based
approach called ‘personalized vaccines’ is more tumor specific since these therapies target
neoantigens or TSMAs, that result from somatic alterations. As these therapies are tissue
specific, they yield fewer off-target effects and hence, lowered likelihood of severe adverse
events. To administer such vaccines, different types of vaccine platforms have been tested
and employed in different settings, as explained in the next section.

1.4.5 Vaccine platforms for neoantigen-based therapy
Once a list of strong binding neoantigens has been identified and validated in vitro, a vaccine
platform is required for therapeutic administration into the patient. Multiple vaccine
platforms are being explored for personalized cancer vaccines, some of which are elucidated
below68:
a) DNA vaccines: This vaccine platform involves constructing a circularized DNA insert
carrying one or more encoded neoantigenic peptide sequences and inserting the
construct into a DNA vector. One important consideration in the design of these
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vaccines is the order of neoantigenic sequences along with spacer sequences such that
no new strong binding junctional epitope is encoded by the resulting sequence. The
DNA vaccine platform is relatively inexpensive to produce as a GMP-grade construct
because DNA synthesis is rapid, automated and inexpensive, and DNA sequencing
can be used to verify the final sequence of the construct prior to administration. These
attributes also would enable rapid scalability of DNA vaccines for precision medicine
applications in cancer therapy, if warranted.

b) Peptide-based vaccines: This vaccine platform involves the direct administration (by

intramuscular injection) of synthetic neoantigenic peptide cocktails suspended in
administrative adjuvant solution. A recent publication described the use of this
vaccine platform using synthetic long 15–30-mer peptides suspended in poly-ICLC
(Hiltonol)69 wherein six melanoma patients were immunized with up to 20 distinct
neoantigenic peptides predicted to bind to MHC class I molecules. Peptide vaccines
are relatively more expensive to generate due to the requirement of synthesizing the
peptides under GMP conditions, and don't always solubilize well with one another, so
often several cocktails must be made in the adjuvant and administered separately.
However, peptide based vaccines are easy to characterize, and straightforward to
synthesize, making the platform relatively scalable.

c) RNA-based vaccines: These vaccines are conceptually similar to DNA and peptide
vaccines wherein synthetic RNAs encode the various predicted neoantigenic peptides
evaluated from the patient’s tumor. One of the main advantages of using this approach
is that by using mRNA as the vaccine, it can be readily translated once in the cell in
order to induce antigen-specific T cell immune responses. However, stability of RNA
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molecules and appropriate processing and presentation by antigen presenting cells
remains one of the major challenges of this vaccination strategy. Sahin et al70 used
this vaccine platform to immunize 13 patients with advanced cutaneous melanoma.
Synthetic RNAs encoding five linker-connected 27-mer peptides were formulated
based on neoantigen predictions of both MHC Class I and Class II binders. In this
study, 60% of the candidate neoepitopes elicited some sort of immune response, and
the majority of T cell responses were CD4+, directed against MHC class II-restricted
antigens.

d) Dendritic cell (DC) based vaccines: These vaccines involve collection of circulating
blood, from which isolated dendritic cells are matured ex vivo in the presence of
neoantigenic peptides. The matured dendritic cells are infused into the same patient. A
recent melanoma trial by Carreno et al71 used this strategy in three melanoma patients,
who had been pretreated with ipilimumab. These patients were vaccinated with DC
loaded with about 7 neoantigenic derived from each patient’s tumor. Only a subset of
the candidates showed existing or de novo immune responses, thus underscoring the
difficulties of predicting peptides that will be processed and presented.

Using tumor specific neoantigens, these vaccine platforms and the associated trials have
shown that there are few, if any, severe adverse events and little cross-reactivity to the wild
type (normal) peptide. These initial clinical trials69,70,71 show promising results about the
safety and tolerance of vaccines that employ neoantigens for cancer therapy. Two of these
studies further treated patients that had a recurrent/progressive disease with checkpoint
blockade therapy (anti-PD1)72 and clinically significant disease regression was reported,
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showing value in the use of combinations such as neoantigen-based vaccines with immune
checkpoint blockade.

Another type of therapy that employs the use of neoantigens, though not directly in the form
of vaccines, is adoptive T cell transfer therapy (ACT). This type of therapy pioneered by
Rosenberg et al. involves removing tumor-specific T cells, either from peripheral blood or the
resected tumor, and expanding them ex vivo which allows them to regain their cytotoxic
function, such that when they are transferred back into the patient, they can drive tumor
elimination. ACT, when used on patients with solid tumors41,73 showed measurable T-cell
specific immune responses against neoantigens. Following treatment with ACT in pilot trials,
it has been shown74 that 40% of treated patients experienced complete regressions of all
measurable lesions for at least five years. While ACT provides another tumor-specific
approach for treatment with fewer side effects, these therapies are costly due to the need for
ex vivo expansion of patient-specific T cells for each patient.
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Figure 1.3: Overview of personalized vaccine design process: Figure originally published
in Liu and Mardis45. Tumor tissue and blood normal samples are extracted from the patient
and exome and RNA sequencing is performed, followed by read alignment and variant
calling algorithms to identify and confirm expression of somatic mutations. This input is used
to determine strong binding neoantigens by using MHC class I & class II epitope prediction
algorithms. The selected set of high quality neoantigens are further prioritized by ELISPOT
and peptide binding assays, before being incorporated in a vaccine.
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1.5

Development and improvement of sequencing

methods for neoantigen characterization
Methods to more accurately identify which tumor-specific mutant peptides (neoantigens) can
elicit anti-tumor T cell immunity are needed if the pursuit of personalized vaccine therapy
and adoptive T cell therapy continues to advance in medical care of cancer patients.
Although the cost-related barriers to producing somatic mutations from MPS data sets have
fallen away with new instrumentation and analytical improvements, barriers to facile use of
computational analyses that yield neoantigen predictions still remain and, if not addressed,
diminish the widespread adoption of this approach to cancer treatment. Since the mutational
repertoire of a typical cancer genome can vary anywhere from 50 to 500+ mutations, there
was a need for a strategy that integrates somatic mutation calls from MPS data, identifies the
neoantigens in the context of the patient’s HLA alleles, and parses out a list of optimal
peptides for downstream testing, as illustrated in Figure 1.3. Chapter 2 describes such a
genome-guided in silico approach to identifying tumor neoantigens that starts with a simple
list of somatic nonsynonymous point mutations from which it predicts high affinity
neoantigens refined by sequencing coverage and gene expression data. Such a pipeline has
been utilized in several first-in-human clinical trials of patient-specific vaccines using
different vaccine platforms, including DNA-based and dendritic cell-based vaccines. We
have further refined the approach to neoantigen prediction from that presented in Chapter 2
by testing the impact of regional-specific adjustments to peptide sequences entering
consideration for MHC binding affinity predictions. Namely, this approach accounts for the
individual-specific variants in the germline, as well as the adjacent somatic alterations that
occur most frequently in high mutation load tumors, proximal to the variant being evaluated
for neoantigen binding. This correction in germline proximal variants is often not done
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because there is an assumption that the human reference genome is representative of the
patient’s inherited variants, some of which may change amino acid sequence in the resulting
peptide. All of these assumptions can lead to incorrect determination of neoantigenic peptide
sequences and to incorrect binding affinities as a consequence. Chapter 3 describes our
results from studying the effect of proximal sequence correction on the calculated binding
affinities and suggests a corrective approach that, in some cases, dramatically impacts the
calculated binding affinity.

We also recognized that neoantigen vaccine therapies may be applied in cancers without high
mutational loads, and that the challenges of identifying a sufficient number of neoantigens to
construct a vaccine might be challenging in this circumstance. Hence, we sought to increase
the numbers of variants that could be evaluated for MHC binding by including rarer types of
variants, including frameshift indel and gene fusions, into neoantigen prediction. In addition,
since there is evidence that MHC Class II binding neoantigens are appropriate to include in
vaccines70, we also wanted to include these predictions into our established pipeline
described in Chapter 2. Chapter 4 describes a modular computational framework to facilitate
each of the critical stages of neoantigen characterization. It integrates the information from
Chapters 2 and 3 into a toolkit that enables neoantigen prediction from the breadth of somatic
alterations including point mutations, insertions, deletions, and gene fusions. Furthermore,
prioritization and selection of these neoantigens for non-informatics savvy users is provided
through a graphical web-based interface. Lastly, this revised approach provides a
functionality to determine the optimal order of selected neoantigen candidates in a DNA
vector-based vaccine.
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Chapter 2: pVAC-Seq: A genome-guided in
silico approach to identifying tumor
neoantigens
Hundal, Jasreet et al. pVAC-Seq: A genome-guided in silico approach to identifying tumor
neoantigens Genome Med. 8, 11 doi:10.1186/s13073-016-0264-5 (2016).
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2.1 Introduction
Cancer immunotherapy has gained significant momentum from recent clinical successes of
checkpoint blockade inhibition. Massively parallel sequence analysis suggests a connection
between mutational load and response to this class of therapy. Methods to identify which
tumor-specific mutant peptides (neoantigens) can elicit anti-tumor T cell immunity are
needed to improve predictions of checkpoint therapy response and to identify targets for
vaccines and adoptive T cell therapies. Here, we present a flexible, streamlined
computational workflow for identification of personalized Variant Antigens by Cancer
Sequencing (pVAC-Seq) that integrates tumor mutation and expression data (DNA- and
RNA-Seq). pVAC-Seq is available at https://github.com/griffithlab/pVAC-Seq.

2.2 Background
Boon et al. were the first to demonstrate that cancer-specific peptide/MHC class 1 complexes
could be recognized by CD8+ T cells present in cancer patients75. Substantial evidence now
suggests that anti-tumor T cells recognize tumor somatic mutations, translated as single
amino acid substitutions, as ‘neoantigens’. These unique antigenic markers arise from
numerous genetic changes, acquired somatically that are present exclusively in tumor
(mutant) and not in normal (wild-type (WT)) cells76. Recent preclinical data indicate that
these mutated proteins, upon processing and presentation in the context of MHC molecules
expressed by antigen-presenting cells, can be recognized as ‘non-self’ by the immune system.
Our previous work in murine sarcoma models was one of the first demonstrations of how
somatic cancer mutations could be identified from massively parallel sequencing, and when
considered in the context of MHC binding affinity, can predict tumor specific neoantigens38.
A subsequent study further demonstrated that these neoantigens were the same epitopes
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recognized by anti-PD1 and anti-CTLA4 checkpoint blockade therapies and that peptide
vaccines comprising neoantigens could provide prophylactic effects. Several other studies
have also characterized these neoantigens as being derived from somatically mutated genes in
mouse 39 as well as in humans40–43, and have shown that they can be recognized by T cells.

While checkpoint blockade therapies have achieved tremendous success in the clinic, patientspecific vaccines still meet a clinical need in those patients that either do not respond,
develop resistance, or cannot tolerate the associated side effects of checkpoint blockade
drugs. The main paradigm behind the development of cancer vaccines rests on the
assumption that if the immune system is stimulated to recognize neoantigens, it may be
possible to elicit the selective destruction of tumor cells. Vaccines incorporate these
neoantigen peptides with the aim of enhancing the immune system’s anti-tumor activity by
selectively increasing the frequency of specific CD8+ T cells, and hence expanding the
immune system’s ability to recognize and destroy cancerous cells. This process is dependent
on the ability of these peptides to bind and be presented by HLA class I molecules, a critical
step to inducing an immune response and activating CD8+ T cells77.

As we move from vaccines targeting ‘shared’ tumor antigens to a more ‘personalized’
medicine approach, in silico strategies are needed to first identify, then determine which
somatic alterations provide the optimal neoantigens for the vaccine design. Ideally, an
optimal strategy would intake mutation calls from massively parallel sequencing data
comparisons of tumor to normal DNA, identify the neoantigens in the context of the patient’s
HLA alleles, and parse out a list of optimal peptides for downstream testing. At present,
elements of this ideal strategy exist, but are not available as open source code to permit others
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to adopt these methods into cancer care strategies. This manuscript describes one such
approach, and provides a link to open source code for end users.

For example, to optimize identification and selection of vaccine neoantigens, several in silico
epitope binding prediction methods have been developed57,78–81. These methods employ
various computational approaches such as Artificial Neural Networks (ANN) and Support
Vector Machines (SVM) and are trained on binding to different HLA class I alleles to
effectively identify putative T cell epitopes.

There are also existing software tools (IEDB82, EpiBot83, EpiToolKit84 ) that compile the
results generated from individual epitope prediction algorithms to improve the prediction
accuracy with consensus methods or a unified final ranking. The current implementation of
EpiToolKit (v2.0) also has the added functionality of incorporating sequencing variants in its
Galaxy-like epitope prediction workflow (via its Polymorphic Epitope Prediction plugin).
However, it does not incorporate sequence read coverage or gene expression information
available from massively parallel sequencing datasets, nor can it compare the binding affinity
of the peptide in the normal sample (WT) versus the tumor (mutant). Another multi-step
workflow Epi-Seq85 uses only raw RNA-Seq tumor sample reads for variant calling and
predicting tumor-specific expressed epitopes.

We report herein an open source method called pVAC-Seq that we developed to address the
critical need for a workflow that assimilates and leverages massively parallel DNA and RNA
sequencing data to systematically identify and shortlist candidate neoantigen peptides from a
tumor’s mutational repertoire that could potentially be used in a personalized vaccine after
immunological screening. This automated analysis offers the functionality to compare and
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differentiate the epitopes found in normal cells against the neoepitopes specifically present in
tumor cells for use in personalized cancer vaccines, and the flexibility to work with any userspecified list of somatic variants. Preliminary versions of this pipeline were applied in mouse
models of cancer to identify expressed mutations in cancer cells and characterize tumorspecific mutant peptides that drive T cell-mediated tumor rejection in mice with MCAinduced sarcomas38,39 . More recently, we used this pipeline in a proof-of-concept trial in
melanoma patients, to identify the neoantigen peptides for use in dendritic cell-based
personalized vaccines71.

2.3 Methods
Our in silico automated pipeline for neoantigen prediction (pVAC-Seq) requires several types
of data input from next-generation sequencing assays. First, the pVAC-Seq pipeline requires
a list of non-synonymous mutations, identified by a somatic variant-calling pipeline. Second,
this variant list must be annotated with amino acid changes and transcript sequences. Third,
the pipeline requires the HLA haplotypes of the patient, which can be derived through
clinical genotyping assays or in silico approaches. Having the above-mentioned required
input data in-hand, pVAC-Seq implements three steps: performing epitope prediction,
integrating sequencing-based information, and, lastly, filtering neoantigen candidates. The
following paragraphs describe the analysis methodology from preparation of inputs to the
selection of neoantigen vaccine candidates via pVAC-Seq (Figure 2.1).

33

Figure 2.1. Overview of the pipeline pVAC-Seq: This figure illustrates the methodological
framework behind the pVAC-Seq pipeline. Starting with preparation of inputs, it consists of
three main steps - epitope prediction, integration of sequencing information, and filtered
candidate selection.

2.3.1 Prepare input data: HLA typing, alignment, variant detection, and
annotation
As described above, pVAC-Seq relies on input generated from the analysis of massively
parallel sequencing data that includes annotated nonsynonymous somatic variants that have
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been ‘translated’ into mutant amino acid changes, as well as patient-specific HLA alleles.
Importantly, these data can be obtained from any appropriate variant calling, and annotation
pipeline and HLA typing approach. Here, we outline our preparatory steps to generate these
input data71. Somatic variant analysis of exome sequencing datasets was performed using the
Genome Modeling System (GMS)86 for alignment and variant calling. In brief, BWA
(version 0.5.9)87 was used for alignment with default parameters, except that the number of
threads was set to 4 (-t 4) for faster processing, and the quality threshold for read trimming to
5 (-q 5). The resulting alignments were de-duplicated via Picard MarkDuplicates (version
1.46) 88.

In cases where clinically genotyped HLA haplotyping calls were not available, we used in
silico HLA typing by HLAminer (version 1)50 or by Athlates49 . HLA typing was performed
on the normal (peripheral blood mononuclear cells), rather than the tumor sample. Though
the two software tools were >85% concordant in our test data (unpublished data), it is helpful
to use both algorithms in order to break ties reported by HLAminer (see below).
I.

HLAminer for in silico HLA-typing using Whole Genome Sequencing (WGS) data:
When predicting HLA class I alleles from WGS data, we used HLAminer in de novo
sequence alignment mode89 by running the script HPTASRwgs_classI.sh, provided in
the HLAminer download, with default parameters. (The download includes detailed
instructions for customizing this script, and the scripts on which it depends, for the
user’s computing environment.) For each of the three HLA loci, HLAminer reports
predictions ranked in decreasing order by score, where ‘Prediction #1’ and ‘Prediction
#2’ are the most likely alleles for a given locus. When ties were present for Prediction
1 or Prediction 2, we used all tied predictions for downstream neoepitope prediction.
However, it should be noted that most epitope prediction algorithms, including
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NetMHC57,80 only work with an algorithm-specific subset of HLA alleles, so we are
constrained to the set of NetMHC-compatible alleles. The current version NetMHC
v3.4 supports 78 human alleles.

II.

Athlates for in silico HLA-typing using exome sequence data: We diverged from the
recommended Athlates protocol at two points: (1) We performed the alignment step,
in which exome sequence data from the normal tissue sample are aligned against
reference HLA allele sequences present in the IMGT/HLA database90, using BWA
with zero mismatches (params : bwa aln -e 0 -o 0 -n 0) instead of NovoAlign91 with
one mismatch. (2) In the subsequent step, sequence reads that matched, for example,
any HLA-A sequence from the database were extracted from the alignment using
bedtools92 instead of Picard. This procedure is resource-intensive, and may require
careful resource management. Athlates reports alleles that have a Hamming distance
of at most 2 and meet several coverage requirements. Additionally, it reports ‘inferred
allelic pairs’, which are identified by comparing each possible allelic pair to a longer
list of candidate alleles using a Hamming distance-based score. We typically used the
inferred allelic pair as input to subsequent steps in the neoepitope prediction pipeline.

After alignments (and optional HLA typing) were completed, somatic mutation detection was
performed using the following series of steps (1) Samtools 93,94 mpileup v0.1.16 was run with
parameters ‘-A -B’ with default setting for the other parameters. These calls were filtered
based on GMS ‘snp-filter v1’ and were retained if they met all of the following rules: (a) Site
is greater than 10 bp from a predicted indel of quality 50 or greater; (b) The maximum
mapping quality at the site is ≥40; (c) Fewer than three single-nucleotide variants (SNV) calls
are present in a 10 bp window around the site; (d) The site is covered by at least three reads
36

and less than 1 × 109 reads; and (e) Consensus and SNP quality is ≥20. The filtered Samtools
variant calls were intersected with those from Somatic Sniper95 version 1.0.2 (params: -F vcf
q 1 -Q 15), and were further processed through the GMS ‘false-positive filter v1’ (params: -bam-readcount-version 0.4 --bamreadcount-min-base-quality 15 --min-mapping-quality 40 -min-somatic-score 40). This filter used the following criteria for retaining variants: (a) ≥1%
of variant allele support must come from reads sequenced on each strand; (b) variants must
have ≥5% Variant Allele Fraction (VAF); (c) more than four reads must support the variant;
(d) the average relative distance of the variant from the start/end of reads must be greater than
0.1; (e) the difference in mismatch quality sum between variant and reference reads must be
less than 50; (f) the difference in mapping quality between variant and reference reads must
be less than 30; (g) the difference in average supporting read length between variant and
reference reads must be less than 25; (h) the average relative distance to the effective 3’ end
of variant supporting reads must be at least 0.2; and (i) the variant must not be adjacent to
five or more bases of the same nucleotide identity (for example, a homopolymer run of the
same base). (2) VarScan Somatic version 2.2.696,97 was run with default parameters and the
variant calls were filtered by GMS filter ‘varscan-high-confidence filter version v1’. The
‘varscan-high-confidence v1’ filter employed the following rules to filter out variants: (a) P
value (reported by Varscan) is greater than 0.07; (b) Normal VAF is greater than 5%; (c)
Tumor VAF is less than 10%; or (d) less than two reads support the variant. The remaining
variant calls were then processed through false-positive filter v1 (params: --bam-readcountversion 0.4 --bamreadcount-min-base-quality 15) as described above. (3) Strelka version
1.0.10 98(params: isSkipDepthFilters = 1).
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Our GMS pipeline expects a matched normal sample for filtering out potentially rare
germline variants. However, in the absence of a matched normal tissue, the dbSNP and 1000
Genome databases could be used for filtering these variants.

The consolidated list of somatic mutations identified from these different variant-callers was
then annotated using our internal annotator as part of the GMS pipeline. This annotator
leverages the functionality of the Ensembl database99 and Variant Effect Predictor (VEP)5.

We wish to emphasize that any properly formatted list of annotated variants can be used as
input to subsequent steps in the pipeline. From the annotated variants, there are two critical
components that are needed for pVAC-Seq: amino acid change and transcript sequence. Even
a single amino acid change in the transcript arising from missense mutations can alter the
binding affinity of the resulting peptide with the HLA class I molecule and/or recognition by
the T cell receptor. Larger insertions and deletions like those arising from frameshift and
truncating mutations, splicing aberrations, gene fusions, and so on may also result in potential
neoantigens. However, for this initial version of pVAC-Seq, we chose to focus our analysis
on only missense mutations.

One of the key features of our pipeline is the ability to compare the differences between the
tumor and the normal peptides in terms of the peptide binding affinity. Additionally, it
leverages RNA-Seq data to incorporate isoform-level expression information and to quickly
cull variants that are not expressed in the tumor. To easily integrate RNA-Seq data, both
transcript ID as well as the entire WT transcript amino acid sequence is needed as part of the
annotated variant file.
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2.3.2 Perform epitope prediction
One of the key components of pVAC-Seq is predicting epitopes that result from mutations by
calculating their binding affinity against the HLA class I molecule. This process involves the
following steps for effectively preparing the input data as well as parsing the output (Figure
2.2).

Figure 2.2 Generation of peptide sequences and filtering predicted epitope candidates. a
Amino acid FASTA sequence is built using 10 flanking amino acids on each side of the
mutated amino acid. The preceding or succeeding 20 amino acids are taken if the mutation
lies near the end or beginning of the transcript, respectively. b All predicted candidate
peptides from epitope prediction software based on selected k-mer window size. c Only
localized peptides (those containing the mutant amino acid) are considered to compare to
WT counterpart. d The ‘best candidate’ (lowest MT binding score) per mutation is chosen
across all specified k-mers and between all independent HLA allele types that were used as
input
Generate FASTA file of peptide sequences

39

Peptide sequences are a key input to the MHC binding prediction tool, and the existing
process to efficiently compare the germline normal with the tumor is very onerous. To
streamline the comparison, we first build a FASTA file that consists of two amino acid
sequences per variant site: WT (normal) and mutant (tumor). The FASTA sequence is built
using approximately eight to 10 flanking amino acids on each side of the mutated amino acid.
However, if the mutation is towards the end or beginning of the transcript, then the preceding
or succeeding 16 to 20 amino acids are taken, respectively, as needed, to build the FASTA
sequence. Subsequently, a key file is created with the header (name and type of variant) and
order of each FASTA sequence in the file. This is done to correlate the output with the name
of the variant protein, as subsequent epitope prediction software strips off each FASTA
header.

Run epitope prediction software
Previous studies100,101 have shown that allele-specific epitope prediction software, such as
NetMHC, perform slightly better when compared to pan-specific methods such as
NetMHCpan58,65,102 in case of well-characterized alleles due to availability of large amounts
of training data. However, pan-specific methods could be beneficial in cases where there is
limited peptide binding data for training, for arbitrary HLA molecules, or when predicting
epitopes for non-human species. We do anticipate adding this support for additional
softwares in upcoming versions of pVAC-Seq. To predict high affinity peptides that bind to
the HLA class I molecule, currently only the standalone version of NetMHC v3.4 is
supported. The input to this software is the HLA class I haplotype of the patient, determined
via genotyping or using in silico methods, as well as the FASTA file generated in the
previous step comprising mutated and WT 17-21-mer sequences. Typically, antigenic
epitopes presented by HLA class I molecules can vary in length and are in the range of eight
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to 11 amino acids (aa). Hence, we recommend specifying the same range when running
epitope prediction software.

Parse and filter the output
Starting with the output list of all possible epitopes from the epitope prediction software, we
apply specific filters to choose the best candidate mutant peptides. First, we restrict further
consideration to strong- to intermediate-binding peptides by focusing on candidates with a
mutant (MT) binding score of less than 500 nM. Second, epitope binding calls are evaluated
only for those peptides that contain the mutant amino acid (localized peptides). This filter
eliminates any WT peptides that may overlap between the two FASTA sequences. Our
workflow enables screening across multiple lengths and multiple alleles very efficiently. If
predictions are run to assess multiple epitope lengths (for example, 9-mer, 10-mer, and so
on), and/or to evaluate all patient’s HLA-A, -B, and -C alleles, we review all localized
peptides and choose the single best binding value representative across lengths (9 aa, 10 aa,
and so on) based on lowest binding score for MT sequence. Furthermore, we choose the ‘best
candidate’ (lowest MT binding score) per mutation between all independent HLA alleles that
were used as input. Additionally, in the output file, the WT peptide binding score is provided.
Although this score may not directly affect candidate choice or immunogenicity, end users
may find this comparative information useful.

2.3.3 Integrate expression and coverage information
We subsequently apply several filters to ensure we are predicting neoantigens that are
expressed as RNA variants, and that have been predicted correctly based on coverage depth
in the normal and tumor tissue datasets. We have found that gene expression levels from
RNA-Seq data, measured as fragments per kilobase of exon per million reads mapped
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(FPKM), provide a good method to filter only the expressed transcripts. We used the tuxedo
suite - Tophat103,104 and Cufflinks105 - as part of the GMS to align RNA-Seq data and
subsequently infer gene expression for our in-house sequencing data. Depending on the type
of RNA prep kit, Ovation® RNA-Seq System V2 (NuGEN Technologies, Inc., San Carlos,
CA, USA) or TruSeq Stranded Total RNA Sample Prep kit (Illumina, Inc., San Diego, CA,
USA) used, Tophat was run with the following parameters: Tophat v2.0.8 ‘--bowtieversion = 2.1.0’ for Ovation, and ‘--library-type fr-firststrand --bowtie-version = 2.1.0’ for
Truseq. For Ovation data, prior to alignment, paired 2 × 100bp sequence reads were trimmed
with Flexbar version 2.21106 (params: --adapter CTTTGTGTTTGA --adapter-trim-end LEFT
--nono-length-dist --threads 4 --adapter-min-overlap 7 --maxuncalled 150 --min-readlength
25) to remove single primer isothermal amplification adapter sequences. Expression levels
(FPKM) were calculated with Cufflinks v2.0.2 (params: --max-bundle-length = 10000000 -num-threads 4).

For selecting unique vaccine candidates, targeting the best ‘quality’ mutations is an important
factor for prioritizing peptides. Sequencing depth as well as the fraction of reads containing
the variant allele (VAF) are used as criteria to filter or prioritize mutations. This information
was added in our pipeline via bam-readcount107. Both tumor (from DNA as well as RNA) and
normal coverage are calculated along with the VAF from corresponding DNA and RNA-Seq
alignments.

2.3.4 Filter neoepitope candidates
Since manufacturing antigenic peptides is one of the most expensive steps in vaccine
development and efficacy depends on selection of the best neoantigens, we filter the list of
predicted high binding peptides to the most highly confident set, primarily with expression
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and coverage based filters. The pVAC-Seq pipeline permits user-specified filters, and we
encourage new users to experiment with these cutoffs in order to tailor the pipeline to their
input data and analysis needs. We employ the following filters: (a) Depth based filters: We
filter out any variants with normal coverage <=5× and normal VAF of >=2%. The normal
coverage cutoff can be increased up to 20× to eliminate occasional misclassification of
germline variants as somatic. Similarly, the normal VAF cutoff can be increased based on
suspected level of contamination by tumor cells in the normal sample.

For tumor coverage from DNA and/or RNA, a cutoff is placed at >=10× with a VAF
of >=40%. This ensures that neoantigens from the founder clone in the tumor are included,
but the tumor VAF can be lowered to capture more variants, which are less likely to be
present in all tumor cells. Alternatively, if the patients are selected based on a pre-existing
disease-associated mutation such as BRAF V600E in the case of melanoma, the VAF of the
specific presumed driver mutation can be used as a guide for assessing clonality of other
mutations. Also, other known driver mutations such as KRAS G12/G13 or NRAS Q61 may
be used to determine purity, and to subsequently adjust the VAF filters to target founder
clone mutations. (b) Expression based filters: As a standard, genes with FPKM values greater
than zero are considered to be expressed. We slightly increase this threshold to 1, to eliminate
noise. Alternatively, we analyze the FPKM distribution (and the corresponding standard
deviation) over the entire sample, to determine the sample-specific cutoffs for gene
expression. Spike-in controls may also be added to the RNA-Seq experiment to assess quality
of the sequencing library and to normalize gene expression data. Since alternative splicing
can give rise to multiple transcripts that encompass the variant residue, optionally, all these
transcripts could be included in analysis during the annotation step. However, one should be
careful as this could potentially give rise to transcripts that do not include the variant. Also,
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long transcripts or transcripts with high G/C content might show some bias if RNA-CapSeq is
used but in our experience are generally well represented. The primary goal of using RNA(Cap)Seq data in our method is to address to questions of primary importance: (1) is the gene
expressed at a reasonably high level (for example, FPKM >1); and (2) is the variant allele
expressed in the RNA-seq fragment population.

This filtered list of mutations is manually reviewed via visual inspection of aligned reads in a
genome viewer like IGV108,109 to reduce the retention of obvious false positive mutations.

2.3.5 Dataset
To demonstrate the workings of our in silico pVAC-Seq pipeline, we applied it to four
metastatic melanoma patients, the clinical results for three of whom were described
previously71. In brief, there were three patients (MEL21, MEL38, MEL218) with stage III
resected cutaneous melanoma, all of whom had received prior treatment with ipilimumab,
and one patient (MEL69) with stage IV cutaneous melanoma. All four patients were enrolled
in a phase 1 vaccine clinical trial (NCT00683670, BB-IND 13590) employing autologous,
functionally mature, interleukin (IL)-12p70-producing dendritic cells (DC). Informed consent
for genome sequencing and data sharing was obtained for all patients on a protocol approved
by the Institutional Review Board of Washington University. We performed genomic
analysis of their surgically excised tumors to select candidates for the personalized DC
vaccine. Three of these patients (MEL21, MEL38, MEL69) had multiple metachronous
tumors. Exome sequencing as well as RNA-CapSeq was performed for each of these tumors,
and their corresponding matched normal tissue. The raw exome and transcriptome sequence
data are available on the Sequence Read Archive database: Bioproject PRJNA278450, and
corresponding dbGaP accession: phs001005.
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2.4 Results and Discussion
Since melanoma patients harbor hundreds of mutations, it can be challenging to filter down
and target the best set of potentially immunogenic neoantigens for vaccine design. For each
of the four metastatic melanoma patients, we used the annotated list of SNVs generated using
the GMS strategy described above, and analyzed them via our pVAC-Seq pipeline. As
mentioned earlier, for the demonstration of this workflow, amino acid changes resulting from
only missense mutations were considered for analysis. Table 2.1 shows the breakdown of
these SNVs described previously71 and the data generated in subsequent steps through our
workflow, leading to a high-confidence list of neoepitopes. As part of our local workflow,
NetMHC v3.4 was used as the epitope prediction software to generate HLA class I restricted
epitopes.

MEL21

MEL38

MEL218

MEL69

LN
(2011)

Skin
(2012)

Skin
(2013)

Axilla
(2012)

Breast
(2013)

AbW
all
(2013)

LN
(2005)

Skin /
Limb
(2013)

Skin /
Scalp
(2013)

Total SNVs

702

838

1099

359

402

385

695

256

282

Missense
SNVs

443

515

598

219

247

238

437

141

162

21-mer
FASTA
entries (WT
& MT)
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1004

1002

424

482

462

850

272

314
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Raw
NETMHC
output (9mers)

Parsed
NetMHC
output
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WT with MT)
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*2
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*2
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*2 (HLA-

(HLAA02:01,
HLAA01:01)

(HLAA02:01,
HLAA01:01)

A02:01,
HLAA01:01)

HLAA02:01,
HLAA31:01,
HLAB07:02)

3796 *2

4465 *2

4458 * 2

1871*3

2131*3

(HLAA02:01,
HLAA01:01)

(HLAA02:01,
HLAA01:01)

(HLAA02:01,
HLAA31:01,
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(HLAA02:01,
HLAA31:01,
HLAB07:02)

(HLAA02:01,
HLAA01:01)

5512*3
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(

(HLAA02:01,
HLAA31:01,
HLAB07:02)

6010
*3
(HLAA02:01,
HLAA31:01,
HLAB07:02)

2042
*3
(HLAA02:01,
HLAA31:01,
HLAB07:02)

11050*3
(
HLAA02:01,
HLAA03:01,
HLA-B44:02
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(HLAA02:01,
HLAA11:01)

(HLAA02:01,
HLAA11:01)

3770 *3

1217 *2
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(HLAA02:01,
HLAA03:01,
HLA-B44:02

(HLAA02:01,
HLAA11:01)

(HLAA02:01,
HLAA11:01)

Filter 1:
Binding
based

110

121

144

103

112

111

161

50

65

HLA-A02:01
candidates
only

79

96

111

52

48

46

93

25

34

Filter 2:
Manually
reviewed
HLA-A02:01
candidates
(Exome plus
RNA-Seq)

11

11

12

14

16

16

24

6

12

Filter 3:
Experimental
ly tested

16

14

18

12

Filter 4:
Vaccine
tested

7

7

7

7

Immunogenic
ity

3

3

3

3

Table 2.1 Summary of predicted epitope candidates through pVAC-Seq pipeline
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The table illustrates the number of raw candidates predicted by NetMHC, and the parsing and
filtering strategies applied thereafter to the final list of neoantigen candidates. These
candidates were then communicated to our vaccine design collaborators who evaluated this
list by patient-specific immunological assays (Filters 3 & 4)71

As is evident from Table 2.1, there were multitudes of epitopes reported by NetMHC v3.4 in
its raw format. This number increased even further with the addition of each HLA class I
allele. Using pVAC-Seq, and its recommended thresholds for filtering (binding and coveragebased), we were able to produce a more reasonable list of high affinity HLA class I binding
neoantigen candidates for experimental validation.

These candidate neoantigens were experimentally tested in binding assays and those with
confirmed binding to HLA class I restricting molecules were incorporated in the vaccine
formulation71. Since all of these patients harbor the BRAF V600E mutation, we used its VAF
in each sample as a comparative control of tumor purity and clonality. Integration of variant
coverage information from Exome and RNA-Seq (VAF), as well as mutant expression
information (FPKM), provided additional information needed to make an informed decision
on the number and identity of peptides to include in each patient-specific vaccine (Figure
2.3, Figure 2.4, Figure 2.5, and Figure 2.6).
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Figure 2.3 Landscape of filtered neoantigen candidates in MEL21. This figure illustrates
the landscape of neoantigen vaccine candidates in patient MEL21 after being prioritized
using the pVAC-Seq pipeline. The points represent the overall sequencing information:
exome and RNA VAFs, gene expression in terms of log2 FPKM value, as well log2 fold
change, calculated as the ratio of WT binding affinity over mutant binding affinity.
Recommended exome and RNA VAF cutoffs are also indicated. Candidates that were
incorporated in the vaccine are labeled based on the genes containing these somatic
mutations. Red boxes depict naturally occurring (that is, pre-existing T cell response) and
blue boxes denote vaccine-induced neoantigens that were recognized by T cells. Since BRAF
was used as a guide for assessing clonality of other mutations, it is also shown in each of
three metachronous tumors (from the same patient)
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Figure 2.4 Landscape of filtered neoantigen candidates in MEL38 This figure illustrates
the landscape of neoantigen vaccine candidates in patient MEL38 after being prioritized
using the pVAC-Seq pipeline. The points represent the overall sequencing information:
exome and RNA VAFs, gene expression in terms of log2 FPKM value, as well log2 fold
change, calculated as the ratio of WT binding affinity over mutant binding affinity.
Recommended exome and RNA VAF cutoffs are also indicated. Candidates that were
incorporated in the vaccine are labeled based on the genes containing these somatic
mutations. Red boxes depict naturally occurring (that is, pre-existing T cell response) and
blue boxes denote vaccine-induced neoantigens that were recognized by T cells. Since BRAF
was used as a guide for assessing clonality of other mutations, it is also shown in each of
three metachronous tumors (from the same patient).
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Figure 2.5 Landscape of filtered neoantigen candidates in MEL218 This figure illustrates
the landscape of neoantigen vaccine candidates in patient MEL218 after being prioritized
using the pVAC-Seq pipeline. The points represent the overall sequencing information:
exome and RNA VAFs, gene expression in terms of log2 FPKM value, as well log2 fold
change, calculated as the ratio of WT binding affinity over mutant binding affinity.
Recommended exome and RNA VAF cutoffs are also indicated. Candidates that were
incorporated in the vaccine are labeled based on the genes containing these somatic
mutations. Red boxes depict naturally occurring (that is, pre-existing T cell response) and
blue boxes denote vaccine-induced neoantigens that were recognized by T cells. Since BRAF
was used as a guide for assessing clonality of other mutations, it is also shown.
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Figure 2.6 Landscape of filtered neoantigen candidates in MEL69. This figure illustrates
the landscape of neoantigen vaccine candidates in patient MEL69 after being prioritized
using the pVAC-Seq pipeline. The points represent the overall sequencing information:
exome and RNA VAF cutoffs, gene expression in terms of log2 FPKM value, as well log2 fold
change, calculated as the ratio of WT binding affinity over mutant binding affinity.
Recommended exome and RNA VAFs are also indicated. Candidates that were incorporated
in the vaccine are labeled based on the genes containing these somatic mutations. Red boxes
depict naturally occurring (that is, pre-existing T cell response) and blue boxes denote
vaccine-induced neoantigens that were recognized by T cells. Since BRAF was used as a
guide for assessing clonality of other mutations, it is also shown in both the metachronous
tumors
As shown, if existing epitope prediction software tools were solely used to generate
neoantigen predictions in these patients, it would have been challenging to integrate the filters
as well as the important digital sequencing metrics that ultimately determined the ‘quality’ of
these candidates. By implementing the novel methods reported in this manuscript, we were
able to rapidly streamline the screening and identification of a smaller number of potentially
immunogenic neoepitopes within the landscape of all neoepitopes. This method can be
further extended to include other genomic alterations such as frame-shift insertions and
deletions, splicing aberrations, and gene fusions, which may in some cases cause larger
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changes in epitope binding affinities. We are currently testing approaches to include binding
predictions from frame-shift insertions and deletions by incorporating VEP annotation, and
once tested, will be adding this functionality to the github repository for pVAC-Seq. By
expanding the focus from just somatic point mutations to the entire neoantigen landscape, it
may also be possible to better assess whether neoantigen load itself can serve as a biomarker
for prediction of checkpoint blockade response.

2.5 Conclusions
The current regimen for predicting and screening neoantigens from sequencing data is
laborious and involves a large number of intermediate steps such as creating FASTA files,
running the prediction algorithms (most of the time online), and filtering output for high
binding affinity candidates. Our flexible, automated in silico workflow, pVAC-Seq, provides
higher efficiency and faster turnaround by automating many of these steps. This approach
should help to evaluate tumor-specific neoepitopes in a much-reduced time, thereby
increasing its applicability for clinical use. As we learn from ongoing early mouse and human
trials, the methods developed will help optimize the composition of personalized cancer
vaccines with high precision and will expedite vaccine design to address growing clinical
demand.

2.6 Authors and Contributions
Jasreet Hundal1, Beatriz M. Carreno2, Allegra A. Petti1, Gerald P. Linette2 , Obi L.
Griffith1,2,4,5 , Elaine R. Mardis1,3,4,5,6*, Malachi Griffith1,4,5
52

1

McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO;

2

Department of Medicine, Division of Oncology, Washington University School of Medicine,

St. Louis, MO;
3

Department of Medicine, Division of Genomics and Bioinformatics, Washington University

School of Medicine, St. Louis, MO;
4

Department of Genetics, Washington University School of Medicine, St. Louis, MO;

5

Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO;

6

Department of Molecular Microbiology, Washington University School of Medicine, St.

Louis, MO;
*Corresponding author: emardis@wustl.edu

JH was involved in all aspects of this study including designing and developing the
methodology, analyzing and interpreting data, and writing the manuscript, with input from
MG, OLG, GPL, and ERM. BMC participated in the design of the study, interpreting the
data, and performing immunological and vaccine experiments, and participated in writing the
manuscript. AAP tested and developed HLA-typing methods and was involved in writing the
manuscript. GPL, ERM, and MG oversaw all the work performed and planned experiments.
All authors read and approved the final manuscript.

2.7 Acknowledgements
We are grateful for creative and computational input from Zachary L. Skidmore, Susanna
Siebert, Todd N. Wylie, Jason R. Walker, and Chris A. Miller. We thank Dr. Robert D.
Schreiber for his expertise and guidance on foundational mouse models work. Dr. William E.
53

Gillanders provided important scientific input to the pipeline development work. MG was
supported by the National Human Genome Research Institute (K99 HG007940). OLG was
supported by the National Cancer Institute (K22 CA188163). BC, GPL, and JH were
supported by the National Cancer Institute (R21 CA179695). ERM was supported by the
National Cancer Institute (R21 CA179695) and the National Human Genome Research
Institute (NIH NHGRI U54 HG003079). AAP was supported by the National Human
Genome Research Institute (NHGRI U54 HG003079).

54

Chapter 3: Accounting for proximal
variants improves neoantigen prediction
Hundal, J. et al. Accounting for proximal variants improves neoantigen prediction. Nat.
Genet. doi:10.1038/s41588-018-0283-9 (2018).
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3.1 Introduction
Over the past two decades, approaches to identify and screen for antigens, both self and nonself, have evolved rapidly32,110. This is due in part to advances in sequencing technologies, in
the accuracy of algorithmic identification of somatic variants, and in computational modeling
to predict the binding affinity of the resulting novel, tumor-specific peptides to major
histocompatibility complex (MHC) molecules45. Thus, current immunogenomic approaches
can identify somatic variants that give rise to tumor-specific mutant antigens or ‘neo’antigens and evaluate their ability to bind to MHC Class I and Class II molecules45.

Typically, to evaluate strong-binding neoantigens from genomic sequencing data, the raw
sequencing reads from tumor and normal DNA libraries are aligned to the human reference
genome, and somatic variants are identified by comparison of tumor to normal read
alignments. The resulting somatic variants of interest (SVOI) are then annotated to predict
protein sequence changes and to infer possible neoantigenic peptides. Individual neoantigenic
peptides are selected by sliding an amino acid window (usually 8-11-mers) across the variant
position to consider each possible ‘register’. These peptides are assessed using various
algorithms to predict binding affinity to MHC and determine the strongest binding epitopes.
These predicted neoantigenic peptides are prioritized as we have previously described111. The
cancer vaccine design process, from read alignment to variant calling and neoantigen
prediction typically assumes the reference genome sequence surrounding each somatic
variant is representative of the patient’s genome sequence.

However, any sequence variant proximal to an SVOI in the patient’s genome that differs
from the human reference may alter the amino acid sequence of the resulting peptide (note,
56

proximal is defined here as ‘situated close to’ or ‘nearby’, not the classic genetics meaning of
‘closer to the centromere’). Existing pipelines that are used for computational prediction of
neoantigens from sequencing data, such as MuPeXI112 and pVAC-Seq111, do not explicitly
incorporate patient-specific nearby germline or somatic variants (collectively referred to as
‘proximal variants’ hereafter) into the peptide sequence considered in neoantigen prediction.
Some pipelines such as Vaxrank113 infer the coding sequence from assembly of tumor RNA
reads, thus accounting for both somatic and germline variants implicitly, but this is largely
dependent on the availability of RNA-Seq data. Failing to account for patient-specific nearby
germline or somatic variants (i.e. proximal variants) could impact the efficacy of a vaccine,
possibly resulting in immunization with incorrect peptides or failure to identify highly
neoantigenic peptides.

To investigate these possibilities, we identified somatic and germline variants proximal to
SVOIs in a data set of tumor sequencing studies representing different tissue sites and
mutational loads. For this analysis, given that the upper-bound for the length of MHCbinding peptides (accounting for both Class I and Class II) is typically considered to be 30
amino acids114,115 we chose a nucleotide window of 89 bp upstream and downstream of each
SVOI in which to identify relevant proximal variants (Methods). We limited our analysis to
only include missense proximal variants and SVOIs. We then incorporated these proximal
variants in the final peptide sequences (proximal variant correction; PVC) and re-evaluated
the resulting peptide set using our neoantigen prediction pipeline (pVAC-Seq)111. Our results
suggest that taking individual proximal variation into account can have a significant effect on
the accuracy of neoantigen selection, resulting in a more personalized vaccine design.
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Figure 3.1: Overview of the pipeline for proximal variant correction The steps required for
incorporating and assessing the impact of proximal variants on neoantigen binding
prediction are depicted as a flow diagram. There are three main steps. (A) Alignment and
variant calling of matched tumor (pink) and normal (green) sequencing data. (B) Phasing of
proximal somatic and germline variants: The pink bars represent the tumor sequence reads,
with mismatches/sequencing errors shown in small gray rectangles. For a somatic variant of
interest (SVOI; labeled with a red flag), we scan 89 bp on either side to assess for proximal
germline or somatic SNVs (labeled with blue and orange boxes). These proximal variants are
then phased together to determine linkage. Only proximal variants that are in phase (orange
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box) with the SVOI (red box) are considered for downstream neoantigen analysis. Other (outof-phase) proximal variants (blue box) are ignored. (C) Neoantigen binding predictions are
then assessed after performing proximal variant correction (PVC). The left panel shows the
‘uncorrected’ wildtype and mutant peptides along with their respective binding scores for a
single SVOI example. The right panel shows PVC (‘corrected’) peptides and scores for this
SVOI.

3.2 Methods
3.2.1 Sequence data alignment and variant calling
To investigate the prevalence of proximal variants (germline SNPs or somatic variants), we
analyzed publicly available sequencing data from the TCGA as well as datasets generated inhouse, altogether representing seven different tissue sites. These data sets were chosen to
adequately represent low, medium and high mutational burden tumors.

Analysis of in-house whole genome/exome sequencing datasets was performed as previously
described111,86,116. Briefly, raw sequencing reads from both the tumor and normal were
aligned to the human reference genome sequence (either GRCh37 or GRCh38) using
BWA117, then merged and deduplicated using Picard (see URLs). A combination of three or
four different variant callers was used to identify somatic variants by comparison of tumor
and normal variant calls: Samtools93, Sniper95, Strelka98, and VarScan96,97. These variants
were filtered as previously described118,119 and then manually reviewed using IGV per the
standard operating procedures120 to obtain a list of high confidence variant calls. On average,
80% of the filtered variants passed manual review. Germline variant analysis of the normal
samples was performed using Samtools.
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For the TCGA data, aligned tumor and normal BAMs from BWA (version 0.7.12-r1039) as
well as somatic variant calls from VarScan2 (in VCF format) were downloaded from the
Genomic Data Commons (GDC). We restricted our analysis to only consider ‘PASS’ variants
in these VCFs that are higher confidence than the raw set. Since TCGA does not provide
germline variants, we used GATK’s HaplotypeCaller to perform germline variant calling
using default parameters. These calls were refined using VariantRecalibrator in accordance
with GATK Best Practices121.

For this study, we restricted the variant calls to only include missense SNVs, in both- TCGA
as well as in-house datasets.

3.2.2 Phasing of variants to assess linkage
Somatic and germline missense variant calls from each sample were combined using
GATK’s CombineVariants, and the variants were subsequently phased using GATK’s
ReadBackedPhasing algorithm.
In silico HLA-typing
OptiType48 was used to perform in silico HLA typing for the in-house samples. For the
datasets downloaded from TCGA, existing in silico HLA typing information was obtained
from The Cancer Immunome Atlas (TCIA122) database.

3.2.3 Choosing an appropriate window for neoantigen analysis
Due to the absence of patient-specific HLA Class II typing information, we limited our
neoantigen binding prediction analysis to MHC Class I, though we believe that the Class II
peptides are also important in contributing to immunogenicity. Hence, our nucleotide window
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was chosen such that it encompasses both Class I and Class II MHC peptide lengths, to
demonstrate the prevalence of proximal variants within that genomic region. Most strongbinding Class I MHC peptides are around 8-11 amino acids in length. There is no length
restriction on Class II MHC peptides due to an open binding groove, and longer peptide
lengths are much more common, typically 13-25-mers123 but peptides as long as 30-mer have
been reported114,115. The majority (99.2%) of human linear T-cell epitopes with MHC class II
restriction currently reported in IEDB 82are 8-30-mers. To identify the best binding 30-mer
around a missense variant of interest, one would ideally scan 29 amino acids upstream and
downstream of the mutant (MT) amino acid, hence a window of 59 amino acids. At the
nucleotide level, this corresponds to 87 nucleotides. Given that the frame of the missense
mutation is not always known, we allow for 2 extra bases leading to a window size of 89
nucleotides on each side of the SVOI.

The appropriate nucleotide window for any peptide length can be calculated using this
formula: ((peptide length -1)*3)+2.

3.2.4 Corrected neoantigen binding prediction using pVACtools
For each sample, the phased variant calls as well as the somatic variant calls were annotated
using Variant Effect Predictor (VEP4), specifically using the Downstream plugin as well as
the custom Wildtype plugin, available via pVACtools (see URLs) . To evaluate the effect of
relevant nearby variants on neoantigen identification, we re-assessed the binding affinities of
the neoantigens with the corrected mutant peptide sequence (Figure 3.1C), using
NetMHCv4.056,57 via an updated version of the pVACtools software. This version takes as
input the VEP-annotated phased VCF file of somatic and germline variants, in addition to the
existing VEP-annotated somatic VCF.
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3.2.5 Calculating False Discovery and False Negative Rates
To calculate FNR and FDR, we first determined the number of weak binders before PVC that
were falsely omitted (false negatives (FN)), as well as the number of peptides that were
identified as strong binders before PVC, but whose sequence (MTpeptide) was altered due to
a proximal variant and which were thus incorrectly considered during neoantigen selection
(false positives (FP)). We also calculated the number of peptides that were identified strong
binders before correction and remained unaltered by proximal variants (true positives (TP)).

𝐹𝑁 ∶ 𝑀𝑇𝑠𝑐𝑜𝑟𝑒!"#$%%&#'&( > 500 𝑛𝑀 Λ 𝑀𝑇𝑠𝑐𝑜𝑟𝑒!"##$!%$& < 500 𝑛𝑀
𝐹𝑃 ∶ 𝑀𝑇𝑠𝑐𝑜𝑟𝑒!"#$%%&#'&( < 500 𝑛𝑀 Λ (𝑀𝑇𝑝𝑒𝑝𝑡𝑖𝑑𝑒_𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 ≠ 𝑀𝑇𝑝𝑒𝑝𝑡𝑖𝑑𝑒_𝑢𝑛𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑)
𝑇𝑃 ∶ (𝑀𝑇𝑠𝑐𝑜𝑟𝑒!"#$%%&#'&( < 500𝑛𝑀) Λ (𝑀𝑇𝑝𝑒𝑝𝑡𝑖𝑑𝑒_𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 ≡ 𝑀𝑇𝑝𝑒𝑝𝑡𝑖𝑑𝑒_𝑢𝑛𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑)

𝐹𝑁𝑅 =

𝐹𝑁
𝐹𝑁 + 𝑇𝑃

𝐹𝐷𝑅 =

𝐹𝑃
𝐹𝑃 + 𝑇𝑃

The FNR is then defined as the number of false negatives divided by the number of false
negatives plus the number of true positives. The FDR is defined as the number of false
positives divided by the number of all positive calls, including both true positives and false
positives.

3.3 Results
To determine how frequently proximal variants occur within the vicinity of an SVOI, we
assessed 430 tumors with varying mutational loads identified from whole genome/exome
sequence data of matched normal and tumor tissue (Figure 3.1, Methods). Specifically, data
from 100 cases each of melanoma, hepatocellular carcinoma and lung squamous cell
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carcinoma were obtained from TCGA. We also evaluated data from 48 cases of HER2+
breast cancer, 34 cases of small cell lung cancer, 30 cases of hepatocellular carcinoma, 15
cases of oral squamous cell carcinoma, and one hypermutated glioblastoma (one primary and
two metastatic samples) from in-house studies. After performing alignment and variant
calling, we confirmed the linkage of SVOIs and proximal (somatic or germline) variants by
phasing the variants using GATK124 [Figure 3.1B] (Methods). Then, the list of SVOIs from
each of the samples was intersected with the respective lists of in-phase amino acid-altering
proximal variants to assess their presence within the chosen nucleotide window.

3.3.1 Missense variants overlap with missense proximal variants
Out of 430 tumor samples analyzed, 380 samples (88.3%) had at least one (range: 1 to 377)
missense SVOI in phase with a proximal missense variant. Of a total of 103,673 missense
variants identified in these tumors, there were 7,783 SVOIs (7.5%) with a proximal missense
variant (somatic or germline) within 89 nucleotides on either side. 5,344 of these missense
SVOIs (5.1%) were also in phase with their respective proximal variants. In most cases
(93.8%), SVOIs had a single proximal germline or somatic variant in phase, but occasionally
multiple (range: two to six) variants were proximal to the SVOI. An average of 241 missense
somatic variants were analyzed per sample. Per patient, an average of 6.5% of SVOIs had a
proximal missense variant, and 5% had one or more proximal missense variants in phase with
the SVOI. On average, 62.2% of these proximal variants were germline missense variants and
37.7% were somatic missense variants. The majority (68.0%) of proximal somatic variants
were contributed by Dinucleotide Polymorphisms (DNPs). Most variant callers (including
those used for the harmonized analysis of TCGA data in the Genomic Data Commons) report
DNPs as two separate SNVs. Excluding the DNPs, on average, 88.4% of the proximal
variants were germline missense SNPs, and 11.6% were somatic missense SNVs.
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3.3.2 Predicted binding affinity changes with PVC
To identify neoantigens capable of eliciting an effective anti-tumor T-cell response, it is
critical to both determine the correct tumor specific peptide sequence and assess its ability to
bind MHC125. First, we sought to assess how accounting for proximal variants in the
neoantigen peptide sequence may influence binding affinity to MHC. In order to evaluate
this, we quantified the impact of missing or incorrectly selecting strong-binding neoantigens
when ignoring proximal variants. We compared binding affinity scores before and after PVC
for each patient’s peptides against their respective MHC Class I alleles.

A typical Class I neoantigen binding evaluation and screening is carried out by sliding over
shorter sub-peptide registers111. To evaluate strong-binding Class I neoantigens of lengths 811-mers, we ideally scan 7-10 amino acids on each side of the mutated amino acid resulting
from the SVOI. Even if a proximal variant alters an amino acid in the full peptide window, it
may not be included in every register we consider as a candidate neoantigen (Figure 3.2).

Figure 3.2 Example of candidate neoantigen evaluation This figure shows the possible subpeptide registers for selection of a candidate neoantigen of length 9. The 17-mer peptide
window for a 9-mer candidate is selected by scanning 8 amino acids on each side of the
mutated amino acid resulting from the SVOI (red box). Only those registers that contain
amino acid changes resulting from both - the proximal variant (PV; orange box), as well as
the SVOI (red box) were considered for this analysis (five peptides shown in yellow for this
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example). The remaining registers shown (grey boxes) contain the SVOI but are not affected
by the proximal variant.

In some rare cases, a proximal variant may translate to the same amino acid sequence as the
SVOI, or the SVOI and proximal variant both lead to amino acid changes if considered in
isolation, but if they are in phase and considered together, they result in no change to the
amino acid sequence. To take into account these cases and accurately assess the effect of
amino-acid changes due to proximal variants on binding predictions, we only considered
those registers that contained both the proximal variant and the SVOI amino acid changes,
when translated together. Across 8-11-mers, on average 45.95% of all neoantigen peptide
registers contained both. Figure 3.3 summarizes the effect of proximal variants on
neoantigen binding affinity. Although the effect is less pronounced for 8-mers, the smallest
length we examined, we see drastic changes in binding affinity due to PVC across all four
peptide

lengths

(represented

as

log10

of

mutant

(MT)

epitope

fold

change

(MTuncorrected/MTcorrected), with ranges spanning from -3.0 to 3.1 for 8-11-mers (Figure 3.3A).
Figures 3.3C-D show the distribution of log(MT fold change) scores for 9-mer and 10-mer
peptides, respectively. For both peptide lengths, most weak binders stay within the same
range before and after PVC but very few strong binders remain unchanged, after PVC. We
chose 500 nM as the binding affinity cutoff for a potential binder, as most known T-cell
epitopes have an affinity value of less than 500 nM126. For the binding prediction changes, we
only considered a call as erroneous if PVC yielded at least a 10% change in predicted binding
affinity.
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Figure 3.3 Mischaracterization of neoantigens before proximal variant correction
The effect of accounting for proximal variants in neoantigen selection is summarized in
several ways (n=380 biologically independent samples with at least one proximal variant).
(A) Violin plot (distribution of all data in blue and whiskers indicating max/min values)
showing the change in uncorrected neoantigen binding using the existing approach
(MTuncorrected) versus PVC (MTcorrected), represented as log10 MT fold change (MTuncorrected /
MTcorrected) across 8-11-mers for all variants in phase with the somatic variant of interest. (B)
For 8-11-mer peptides, the False Negative Rate (FNR) (shown as orange bars) represents the
number of instances when a truly strong-binding peptide was mistaken as a weak-binding
peptide (MTuncorrected > 500 nM, and MT fold-change < 1.1 ). The False Discovery Rate
(FDR) (shown in blue bars) represents the number of instances where a strong-binder before
PVC (MTuncorrected < 500nM) is determined to have an incorrect peptide sequence as a result
of a proximal variant. (C) Log10 scaled comparison of corrected versus uncorrected binding
scores for 9-mer peptides considering patient-specific MHC Class I alleles. Dotted lines
demarcate the binding affinity threshold of 500 nM. (D) Log10 scaled comparison of
corrected versus uncorrected binding scores for 10-mer peptides considering patient-specific
MHC Class I alleles.
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3.3.3 Impact of PVC on False Discovery and False Negative Rates
In addition to the effect a proximal amino acid substitution may have on a neoantigen’s
binding potential, it is also important to consider whether the peptide sequence of the selected
neoantigen is correct and representative of the sequence in the tumor. Failure to do so may
affect the immunogenic potential of the neoantigen being selected, as the uncorrected
neoantigen will not produce tumor-specific T-cells, even if it binds well and is presented by
the MHC.

To determine how many neoantigens were being erroneously predicted, and the effect that
mischaracterization of neoantigens due to proximal variants would have on candidate
selection, we calculated the False Negative Rate (FNR) and False Discovery Rate (FDR) after
applying PVC. The FNR and FDR represent probabilities of potential MHC binders (binding
affinity < 500 nM) being discarded (false negatives) and of erroneous peptides being
mistaken for potential binders (false positives), respectively.

An average of 9 SVOI and 10 neoantigenic peptides were mischaracterized per case. As a
consequence, 1,165 potential binders (MTcorrected < 500 nM) were erroneously rejected, and
3,305 peptides which were strong binders before PVC were misidentified across all 430
patients investigated here. Overall, FNR and FDR across lengths 8-11 were 0.026 and 0.069,
respectively (Figure 3.3B).

As a representative example, Figure 3.4 illustrates data from one of the TCGA melanoma
samples with a heterozygous missense SNV in the reverse strand gene MARCH10 that
overlaps an in-phase heterozygous germline single nucleotide polymorphism (SNP), 21
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nucleotides

upstream.

When

translated,

this

germline

SNP

results

in

S357F

(NP_001275708.1:p.Phe357Ser) alteration that is 7 amino acids downstream to the missense
somatic variant F350S (NP_001275708.1:p.Ser350Phe). This variant directly affects the final
neoantigen sequence for a peptide of any length (> 8-mer). To evaluate the effect of this
germline SNP on the binding affinity of the neoantigen peptide, we calculated the binding
affinity of the uncorrected versus the PVC neoantigenic peptides. The binding affinity of the
best register for a 10-mer peptide using the uncorrected approach (MTuncorrected = 55.44 nM) is
within the range for a good binder (< 500 nM). However, after including this patient’s
proximal germline variant, the binding affinity for the same register decreases almost 70-fold
(MTcorrected = 3766.72 nM), thus predicting a very weak binder. Using the uncorrected
analysis approach, one might have selected this neoantigenic peptide for a vaccine but after
PVC, the candidate peptide is unsuitable. This result illustrates the importance of using the
individual variation of the germline genome while selecting and designing neoantigens for
personalized immunotherapy.

Figure 3.4 Example of a germline SNP within the proximity of a somatic SNV An example
from one of the TCGA melanoma samples with a missense SNV that overlaps a germline SNP
(dbSNP ID: rs9891498), 21 nucleotides upstream. When translated, the germline SNP results
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in S357F (NP_001275708.1:p.Phe357Ser) alteration and is 7 amino acids downstream of the
missense somatic variant F350S (NP_001275708.1:p.Ser350Phe) in MARCH10.

3.4 Discussion
There are some caveats/limitations of our approach. Firstly, the analysis was restricted only
to single nucleotide changes (i.e. missense somatic SNVs that are near another germline or
somatic SNV), and did not seek to evaluate whether other, potentially relevant types of
variants were found nearby. These include insertions and deletions (both somatic and
germline)127 and different types of structural variants that often have a more significant
impact on peptide sequences but also are rarer than SNVs. Phasing of indels and structural
variants is also not currently handled by software such as GATK’s ReadBackedPhasing.
Secondly, our analysis ‘window’ (89 bp) was defined in genomic coordinates. It is
substantially more complicated to consider this window size in the context of transcriptome
coordinates, since intronic coordinates must be ignored when scanning upstream and
downstream. This is further complicated in genes with alternative transcripts and hence
multiple introns and exons to consider. Our ability to determine phase for variants separated
by an intron would be limited in WGS or exome data (although could be evaluated in RNAseq data with sufficient read lengths). Lastly, for this study, we only considered neoantigen
binding predictions to MHC Class I molecules. MHC Class II peptides are much longer due
to an open binding groove and hence, the subsequent impact of proximal variants on the
peptide sequence would be even more pronounced. Due to these limitations, our results are
likely an underestimation of the impact of PVC.

Moreover, even with seemingly small false discovery and false negative rates, the importance
of accounting for the effect of proximal variants is clear when we consider clinical vaccine
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design scenarios. For example, 10 or fewer peptides are usually selected for the final vaccine
from a larger number of initial candidates. Given this scenario, we calculated the probability
of choosing at least 1 weak binder or of omitting 1 strong binder in the final vaccine, without
PVC. For the first probability, we calculated 1 - (1-FDR)10 = 0.513 and for the second, we
calculated 1 - (1-FNR)10 = 0.228. The probability that at least one of these errors occurs for
each patient evaluated, is 1 - (1-FDR)10*(1-FNR)10 = 0.624. Thus, for neoantigen
identification in 100 patients, we can expect that approximately 51 patients would receive a
suboptimal vaccine specifically due to receiving a neoantigen with an incorrect peptide
sequence, 23 would receive a suboptimal vaccine specifically due to missing a strong-binding
neoantigen, and 62 would receive a suboptimal vaccine due to at least one of these causes.

Design of personalized cancer vaccines is complex, time consuming, and expensive. Previous
work has shown that only about 16-43% of the predicted neoantigenic peptides included in a
vaccine formulation yield CD8+ T-cell response69–72. Our study demonstrates the importance
of ensuring the selected neoantigens correctly represent the individual’s genome and
therefore maximize the likelihood of eliciting an immune response. PVC based on the
patient’s genome can eliminate errors during neoantigen candidate selection, potentially
increasing the efficacy of personalized vaccines. Further studies may also demonstrate the
importance of considering proximal variants when using neoantigen load to predict response
to checkpoint blockade inhibition therapies.

3.5 Code availability
The proximal variant analysis code has now been added to the proximal_variants branch of
the pVACtools GitHub repository (see URLs). We have also packaged this branch and
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uploaded the package as an alpha release to TestPyPi. The alpha release can be installed by
running `pip install -f https://test.pypi.org/project/pvactools/1.0.8/ pvactools==1.0.8` on the
command line. The feature will be released with the main pVACtools package as part of the
next software release cycle (version 1.1.0).

3.5.1 URLs
Picard: https://broadinstitute.github.io/picard/
pVACtools: http://pvactools.org/
Github

repository

for

proximal

variant

analysis

code:

https://github.com/griffithlab/pVACtools/tree/proximal_variants

3.6 Data availability
Several of the in-house sequencing datasets used in the study have been previously published
and deposited in various databases. All sequence data for the HER2+ breast cancer samples
can be accessed via the Database of Genotypes and Phenotypes (dbGAP; study accession:
phs001291)128. Data for oral squamous cell carcinoma project and hepatocellular carcinoma
samples are part of other manuscripts currently in preparation, and can be accessed under
dbGAP study accession phs001623 and phs001106, respectively. Results for the glioblastoma
case129 and small cell lung cancer119 have been published and can be accessed under dbGAP
study accessions phs001663 and phs001049, respectively. TCGA data can be accessed under
dbGaP study accession phs000178.
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Chapter 4: pVACtools- a computational
toolkit to select and visualize cancer
neoantigens
Hundal J et al. pVACtools: a computational toolkit to select and visualize cancer neoantigens
(2018) Manuscript submitted. doi:10.1101/501817
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4.1 Introduction
Increasing interest in identifying the numbers and types of predicted neoantigens encoded by
a cancer genome has placed an emphasis on the facility and precision of related
computational prediction tools45.

Several such efforts have been published112,113,130.

Typically, these tools start with a list of somatic variants (in VCF or other formats), with
annotated protein changes, and predict the strongest MHC binding peptides (8-11-mer for
class I MHC and 13-25-mer for class II) using one or more prediction algorithms56,57,131. The
predicted neoantigens are then filtered or ranked based on quality metrics including
sequencing read coverage, variant allele fraction, gene expression, and differential binding
compared to the wild type peptide (agretopicity index score
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). However, of the small

number of such prediction tools (Table 4.1), most lack some key functionality, including
predicting neoantigens from gene fusions, aiding optimized vaccine design for DNA cassette
vaccines, and including nearby germline or somatic alterations into the candidate
neoantigens132. An intuitive graphical user interface to visualize and efficiently select the
most promising candidates is also critical to facilitate involvement of clinicians and other
researchers in the process of neoantigen evaluation.
To address these limitations and to add facility for all end-users, we created a comprehensive
and extensible framework for computational identification, selection, prioritization and
visualization of neoantigens - ‘pVACtools’, that facilitates each of the major components of
neoantigen identification. This computational framework can be used to identify neoantigens
from a variety of somatic alterations, including gene fusions and insertion/deletion frameshift
mutations, both of which potentially create very immunogenic neoantigens133. Further,
pVACtools can facilitate both MHC class I and II predictions, and provides an interactive
display of predicted neoantigens for review by the end user.
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pVACtools

Vaxrank113

MuPeXI1

CloudNeo13

FRED2134

Epi-Seq85

ProTect
(https://gi
thub.com/
BD2KGe
nomics/pr
otect)

Variant
calling (within
the pipeline)

N

N

N

N

N

Y

Y

Variant types
supported

SNVs, Inframe
Indels,
Frameshifts,
Gene fusions
(pVACfuse)

SNVs, Indels,

SNVs,
Inframe
Indels,
Frameshif
ts

SNVs

SNVs, Inframe
Indels,
Frameshifts,

SNVs

SNVs

HLA typing
(within the
pipeline)

N

N

N

Y(
PolySolver,
HLAMiner)

Y (via separate
installation of
OptiType,
Polysolver,
Seq2HLA, &
ATHLATES)

N

Y (Phlat)

RNA-Seq
expression
data filter

Y (pVACseq)

Y

Y

N

N

Y

Y

Sequence
coverage &
VAF filter

Y (pVACseq)

Y

Y (only
compatibl
e with
MuTect2
variant
calls)

N

N

Y

N

Algorithms
used for
epitope
binding
affinity
prediction

IEDB (web and
local)

IEDB (web and
local)

netMHCp
an (local
only)

netMHC,
netMHCpan
(local only)

NetMHC
(local
only)

IEDB
(local
only)

(MHC Class I:
NetMHCpan,
NetMHC,
NetMHCcons,
PickPocket,,
SMM,
SMMPMBEC)

MHCflurry,
NetMHC,
NetMHCpan,
NetMHCIIpan,
NetMHCcons,

Local: NetMHC,
NetMHCPan,
NetMHCII,
NetMHCIIpan,
NetCTLpan,
PickPocket

12

0

Included:
Select from,
SMMPMBEC,
syfpeithi, SMM,
Tepitopepan,
ARB,epidemix,
comblibsidney,
Unitope,
HAMMER,
SVMHC,
BIMAS,

MHCflurry
MHCnuggets
(MHC Class II:
NetMHCIIpan,
SMMalign,
NNalign
MHCnuggets)
Stability
prediction

Y
(NetMHCstabpa
n)

N

N

N

Y
(NetMHCstabpa
n)

N

N

Cleavage site
prediction

Y (NetChop)

Y (NetChop)

N

N

Y (ProteaSMM,
PCM, Ginodi,
NetChop)

N

N

Support for
vector
design/epitope
assembly

Y (pVACvector)

N

N

N

Y (OptiVac)

N

N

Incorporation

Y

Y (RNA only)

N

N

N

Y

N
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of proximal
variants

(RefHap)

Unique
epitope
ranking
method

Y

Y (“Total Binding
Score”)

Y
(“Priority
Score”)

N

Y (OptiTope
immunogenicity
score)

N

Y
(Rankboo
st score)

Graphical
User Interface

Y (pVACviz)

N

Y
(http://ww
w.cbs.dtu.
dk/service
s/MuPeXI
/)

Y (via NCI
Cancer
Genomics
Cloud
version)

Y (EpiToolKit
2.0)

N

N

Results
visualization

Y (pVACviz)

N

N

N

N

N

N

HTTP REST
API

Y (pVACapi)

N

N

N

Y

N

N

License

NPOSL-3.0

Apache 2.0

Unknown

Apache 2.0

3-clause BSD

Unknown

Apache
2.0

Table 4.1: Comparison of existing software and tools for cancer immunotherapy analysis

4.2 pVACtools workflow
The pVACtools workflow (Figure 4.1) is divided into flexible components that can be run
independently. The main tools in the workflow are: (a) pVACseq: a significantly enhanced
and reengineered version of our previous pipeline111 for identifying and prioritizing
neoantigens from a variety of tumor-specific alterations (b) pVACfuse: a tool for detecting
neoantigens resulting from gene fusions (c) pVACviz: a graphical user interface web client
for process management, visualization and selection of results from pVACseq (d)
pVACvector: a tool for optimizing design of neoantigens and nucleotide spacers in a DNA
vector that prevents high-affinity junctional epitopes, and (e) pVACapi: an OpenAPI HTTP
REST interface to the pVACtools suite.
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Figure 4.1: Overview of pVACtools workflow: The pVACtools workflow is highly
modularized and is divided into flexible components that can be run independently. The main
tools under the workflow include pVACseq111 for identifying and prioritizing neoantigens
from a variety of somatic alterations (red inset box), pVACfuse (green) for detecting
neoantigens resulting from gene fusions, pVACviz (blue) for process management,
visualization and selection of results and pVACvector (orange) for optimizing design of
neoantigens and nucleotide spacers in a DNA vector. All of these tools interact via the
pVACapi (purple), an OpenAPI HTTP REST interface to the pVACtools suite.
pVACseq111 has been completely implemented in Python3 and extended to include many new
features since our initial report of its use. pVACseq no longer requires a custom input format
for variants, and now uses a standard VCF file annotated with VEP4. In our own neoantigen
identification pipeline, this VCF is the result of merging results from multiple somatic variant
callers and RNA expression tools. Information that is not natively available in the VCF
output from somatic variant callers (such as coverage and variant allele fractions for RNA
and DNA, as well as gene and transcript expression values) now can be added to the VCF
using vcf-annotation-tools (vatools.org), a suite of accessory scripts that we created to
accompany pVACtools. pVACtools queries these features directly from the VCF, enabling
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prioritization and filtering of neoantigen candidates based on sequence coverage and
expression information. In addition, pVACtools now makes use of phasing information
provided in the VCF, taking into account all variants proximal to somatic variants of interest
that alter neoantigen peptide sequences. Since proximal variants can change the neoantigenic
peptide sequence and also affect neoantigen binding predictions, this is an important
confounding factor to ensure that the selected neoantigens correctly represent the individual’s
genome132. We have also expanded the supported mutation types for neoantigen predictions
to include in-frame indels and frameshift mutations. These capabilities expand the potential
number of targetable neoantigens several-fold in many tumors.

To prioritize neoantigens, pVACseq now offers support for as many as eight different MHC
Class I epitope prediction algorithms and four MHC Class II prediction algorithms. The tool
does this by leveraging the Immune Epitope Database (IEDB)135 and their suite of six
different MHC class I prediction algorithms, as well as three MHC Class II algorithms.
pVACseq supports local installation of these tools for power-users, or provides
straightforward access by default via the IEDB RESTful web interface. In addition, pVACseq
now contains an extensible framework for supporting new neoantigen prediction algorithms
that has been used to add support for two new non-IEDB algorithms - MHCflurry61 and
MHCnuggets62. By creating a framework that integrates many tools we allow for (a) a
broader ensemble approach than IEDB, and (b) a system that other users can leverage to
develop improved ensemble ranking, or to integrate proprietary or not-yet-public prediction
software. Importantly, this framework enables non-informatics-savvy users to predict
neoantigens from sequence variant data sets.
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Once neoantigens have been predicted, the pVACseq ranking score is used to prioritize them.
This score takes into account gene expression, sequence read coverage, binding affinity
predictions, and agretopicity. In addition to applying strict binding affinity cutoffs, the
pipeline also offers support for MHC allele-specific cutoffs136. Taking a step further than
most commonly used approaches, we also offer cleavage position predictions via optional
processing through NetChop137 as well as stability predictions made by NetMHCstab138.

Previous studies have shown that the novel protein sequences produced by gene fusions
frequently produce neoantigen candidates139. pVACfuse provides support for predicting
neoantigens from such gene fusions. Fusion variants may be imported in annotated BEDPE
format from any fusion caller (we used INTEGRATE-Neo139). These variants are then
assessed for presence of fusion neo-epitopes using predictions against any of the pVACseqsupported binding prediction algorithms.

Implementing cancer vaccines in a clinical setting requires multidisciplinary teams, many of
whom may not be informatics savvy. To support this growing community of users, we
developed pVACviz, which is a browser-based user interface that assists in launching,
managing, reviewing, and visualizing the results of pVACtools processes. Instead of
interacting with the tools via terminal/shell commands, the pVACviz client provides a
modern web-based user experience. Users complete a pVACseq process setup form that
provides helpful documentation and suggests valid values for inputs. The client also provides
views showing ongoing processes, their logs, and interim data files to aid in managing and
troubleshooting. After a process has completed, users may examine the results as a filtered
data table, or as a scatterplot visualization - allowing them to curate results and save them as
a CSV file for further analysis.
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Figure 4.2: pVACviz GUI client: pVACtools provides a browser-based graphic user
interface, called pVACviz, that provides an intuitive means to launch pipeline processes,
monitor their execution, and analyze, export, or archive their results. To launch a process,
users navigate to the Start Page (A), and complete a form containing all of the relevant
inputs and settings for a pVACseq process. Each form field includes help text, and provides
typeahead completion where applicable. For instance, the Alleles field provides a typeahead
dropdown menu that match available alleles. Once a process is launched, a user may monitor
its progress on the Manage Page (B), which lists all running, stopped, and completed
processes. The Details Page (C) shows a process’ current log, attributes, and any results files
as well as providing buttons for stopping, restarting, exporting and archiving the process.
The results of pipeline processes may be analyzed on the Visualize Page (D), which displays
a customizable scatterplot of a file's rows. The X and Y axis may be set to any column in the
result set, and filters may be applied to values in any column. Additionally, points may be
selected on the scatter plot or data grid (not visible in this figure) for further analysis or
export as CSV files.
Furthermore, to support informatics groups that want to incorporate or build upon the
pVACtools features, we developed pVACapi, which provides a HTTP REST interface to the
pVACtools suite. Currently, it provides the API that pVACviz uses to interact with the
pVACtools suite. Advanced users could develop their own user interfaces, or use the API to
control multiple pVACtools installations remotely over an HTTP network.

Once a list of neoantigen candidates has been prioritized and selected, the pVACvector utility
can be used to aid in the construction of DNA-based cancer vaccines. The input is either the
output file from pVACseq or a fasta file containing peptide sequences, and pVACvector
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returns a neoantigen sequence ordering that minimizes the effects of junctional epitopes
(which may create novel antigens) between the sequences. This is accomplished by using the
core pVACseq services to predict the binding scores for each junctional peptide and by
testing junctions with spacer140 amino acid sequences that may help to reduce reactivity. The
final vaccine ordering is achieved through a simulated annealing procedure that returns a
near-optimal solution, when one exists.

pVACtools has been used to predict and prioritize neoepitopes for several neoantigen
studies141–143 and cancer vaccine clinical trials (e.g. NCT02348320 and NCT03122106). We
also have a large external user community (the original ‘pvacseq’ package has been
downloaded over 37,000 times from PyPi, and the ‘pvactools’ package has been downloaded
over 9,000 times) that has been actively evaluating and using these packages for their
neoantigen analysis, and has also helped in the subsequent refinement of pVACtools through
feedback.

4.3 Methods
To demonstrate the utility and performance of the pVACtools package, we downloaded
exome sequencing and RNA-Seq data from The Cancer Genome Atlas (TCGA)14 from 100
cases each of melanoma, hepatocellular carcinoma and lung squamous cell carcinoma, and
used patient-specific MHC Class I alleles (Figure 4.3) to determine neoantigen candidates
for each cancer.

4.3.1 TCGA data pre-processing
Aligned tumor and normal BAMs from BWA87 (version 0.7.12-r1039) as well as somatic
variant calls from VarScan2144,97 (in VCF format) were downloaded from the Genomic Data
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Commons (GDC, https://gdc.cancer.gov/ ). Since the GDC does not provide germline variant
calls for TCGA data, we used GATK’s145 HaplotypeCaller to perform germline variant
calling using default parameters. These calls were refined using VariantRecalibrator in
accordance with GATK Best Practices121. Somatic and germline missense variant calls from
each sample were then combined using GATK’s CombineVariants, and the variants were
subsequently phased using GATK’s ReadBackedPhasing algorithm.

Phased Somatic VCF files were annotated with RNA depth and expression information using
VCF annotation tools (vatools.org). We restricted our analysis to only consider ‘PASS’
variants in these VCFs as these are higher confidence than the raw set, and the variants were
annotated using the “--pick” option in VEP.

Existing in silico HLA typing information was obtained from The Cancer Immunome Atlas
(TCIA) database122.

4.3.2 Neoantigen prediction
The VEP-annotated VCF files were then run through pVACseq using all eight Class I
prediction algorithms and for epitope lengths 8-11. The current MHC Class I algorithms
supported by pVACseq are NetMHCpan58, NetMHC57,58, NetMHCcons(Karosiene et al.
2012), PickPocket59, SMM63, SMMPMBEC64, MHCflurry61 and MHCnuggets62. The four
MHC Class II algorithms that are supported are NetMHCIIpan, SMMalign, NNalign, and
MHCnuggets. For the demonstration analysis, we limited our prediction to only MHC Class I
alleles due to availability of HLA typing information from TCIA, though predictions of Class
II can be just as easily generated using pVACtools.
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4.3.3 Ranking of Neoantigens
To help prioritize neoantigens, a ranking score is assigned where each of the following four
criteria are assigned a rank-ordered value (where the worst = 1):
B = binding affinity
F = Fold Change between MT and WT alleles
M = mutant allele expression, calculated as (Gene expression * Mutant allele RNA Variant
allele fraction)
D = DNA Variant allele fraction

A final ranking is based on a score obtained from combining these values:
Priority Score = B+F+(M*2)+(D/2). This score is not meant to be the final word on peptide
suitability for vaccines, but was designed to be a useful metric.

4.3.4 Pipeline for creation of pVACtools input files
pVACtools is designed to support a standard VCF variant file format and thus, should be
compatible with many existing variant calling pipelines. However, as a reference, we provide
the following description of our current somatic and expression analysis pipeline (manuscript
in preparation) which has been implemented using docker, CWL146, and Cromwell147. The
pipeline consists of workflows for alignment of exome/DNA- and RNA-Seq data, somatic
and germline variant detection, RNA-Seq expression estimation as well as optional HLA
typing.

This pipeline starts with raw patient tumor exome or cDNA capture148 and RNA-seq data and
produces annotated VCFs for neoantigen identification and prioritization with pVACtools.
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Our pipeline consists of three main components: DNA alignment, variant detection and
annotation, as well as RNA-seq data processing. More specifically, we use BWA-MEM87 for
aligning the patient’s tumor and normal exome data. The output BAM then undergoes
merging (Samtools Merge), query name sort (Picard SortSam), duplicate marking (Picard
MarkDuplicates), position sorting followed by base quality recalibration (GATK
BaseRecalibrator). GATK’s HaplotypeCaller145 is used for germline variant calling and the
output variants are annotated using VEP4 and filtered for coding sequence variants.

For somatic variant calling, our pipeline combines the output of four variant detection
algorithms- Mutect2149, Strelka98, Varscan144,97 and Pindel150. The combined variants are
normalized using GATK’s LeftAlignAndTrimVariants where the indels are left-aligned and
common bases are trimmed. Vt151 is used to split multi-allelic variants. Several filters such as
gnomAD allele frequency, percentage of mapq0 reads, as well as pass-only variants are
applied prior to annotation of the VCF using VEP. We use a combination of custom and
standard plugins for VEP annotation (params: --format VCF --plugin Downstream --plugin
Wildtype --symbol --term SO --transcript_version --tsl --coding_only --flag_pick --hgvs).
Variant coverage is assessed using bam-readcount (https://github.com/genome/bamreadcount) for both the tumor and normal DNA exome data and is also annotated into the
VCF output using VCF-annotation-tools (vatools.org).

Our pipeline also generates a phased-VCF file by combining both the somatic and germline
variants and running the sorted combined variants through GATK ReadBackedPhasing.

For RNA-seq data, the pipeline first trims the adapter sequence using flexbar152 and aligns the
patient’s tumor RNA-seq data using HISAT2153. Two different methods, Stringtie154 and
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Kallisto155, are employed for evaluating both the transcript and gene expression values.
Additionally, coverage support for variants in RNA-seq data can also be assessed through
bam-readcount. This information is added to the VCF using VCF-annotation-tools and serves
as an input for neoantigen prioritization using pVACtools.

Optionally, our pipeline can also run HLA-typing in silico using OptiType48 when clinical
HLA typing is not available.

4.3.5 Implementation of software
pVACtools is written in Python3. The individual tools are implemented as separate command
line entry points that can be run using the `pvacseq`, `pvacfuse`, `pvacvector`, `pvacapi`, and
`pvacviz` commands to run the respective tool. pVACapi is required to run pVACviz so both
the `pvacapi` and `pvacviz` command need to be executed in separate terminals. For
pVACseq, the PyVCF package is used for parsing the input VCF files. The mhcflurry and
mhcnuggets packages are used to run the MHCflurry and MHCnuggets prediction algorithms,
respectively. The pandas package is used for data management while filtering and ranking the
neoantigen candidates in pVACseq and pVACfuse. The simanneal package is used for the
simulated annealing procedure when running pVACvector. pVACapi is implemented using
Flask and Bokeh. The pVACviz client is written in TypeScript using the Angular web
application framework, the Clarity UI component library, and the ngrx library for managing
application state. The test suite is implemented using the Python unittest framework and
GitHub integration tests are run using travis-ci (travis-ci.org). Code changes are integrated
using GitHub pull requests

(https://github.com/griffithlab/pVACtools/pulls). Feature

additions, user requests, and bug reports are managed using the GitHub issue tracking
(https://github.com/griffithlab/pVACtools/issues). User documentation is written using the
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reStructuredText markup language and the Sphinx documentation framework (sphinxdoc.org). Documentation is hosted on Read The Docs (readthedocs.org).

4.4 Results and Discussion
4.4.1 Analysis of TCGA data using pVACtools
To demonstrate the utility and performance of the pVACtools package, we downloaded
exome sequencing and RNA-Seq data from The Cancer Genome Atlas (TCGA)14 from 100
cases each of melanoma, hepatocellular carcinoma and lung squamous cell carcinoma, and
used patient-specific MHC Class I alleles (Figure 4.3) to determine neoantigen candidates
for each patient. There were a total of 64,422 VEP-annotated variants reported across 300
samples, with an average of 214 variants per sample. Of these, 61,486 were single
nucleotides variants (SNVs), 479 were inframe insertions and deletions and 2,465 were
frameshift mutations (Figure 4.4). We used this annotated list of variants as input to the
pVACseq component of pVACtools to predict neoantigenic peptides. pVACseq reported
14,599,993 unfiltered peptide candidates. The original version of pVACseq111 reported
10,284,467 peptides, and thus, by extending support for additional variant types as well as
prediction algorithms (due to support for additional alleles), we produced 42% more raw
candidate neoantigens.
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(a)

(b)
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(c)

Figure 4.3: Patient counts per HLA allele subtype Distribution of HLA-alleles for the entire
cohort of 300 TCGA patients analyzed in this study is shown in each of the three plots for (a)
HLA-A allele subtypes (33 unique alleles); (b) HLA-B allele subtypes (67 unique alleles); (c)
HLA-C allele subtypes (30 unique alleles). The total number of unique HLA alleles found in
the patient cohort was 130.
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Figure 4.4: Violin plots showing the distribution of observed variants per cancer type
summarized for each variant type supported by pVACseq. (A) missense (total variant count:
61,486), (B) inframe deletion (total variant count: 389), (C) inframe insertion (total variant
count: 81), and (D) frameshift (total variant count: 2,465).

By applying our default median binding affinity cutoff of 500 nM across all eight MHC Class
I prediction algorithms, there were 96,235 predicted strong binding neoantigens, derived from
34,552 somatic variants (32,788 missense SNVs, 1,603 frameshift variants and 131 in-frame
indels). This set of strong binders was further reduced by filtering out mutant peptides with
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median predicted binding affinities (across all prediction algorithms) greater than that of the
corresponding wildtype peptide (i.e. mutant/wildtype binding affinity fold change > 1),
resulting in 70,628 neoantigens from 28,588 variants (26,880 SNVs, 1,583 frameshift and
125 in-frame indels).

This set was subsequently filtered by evaluation of exome sequencing data coverage and our
recommended defaults, as follows. By applying the default criteria of variant allele fraction
(VAF) cutoff of > 25% in tumor and < 2% in normal sample, with coverage levels of at least
10X tumor coverage and at least 5X normal coverage, 10,730 neoantigens from 4,891
associated variants (4,826 SNVs, 56 frameshift and 9 in-frame indels) were obtained, with an
average of 36 neoantigens predicted per case. Since RNA-seq data also were available, the
filtering criteria included RNA-based coverage filters (tumor RNA VAF > 25% and tumor
RNA coverage > 10X) as well as a gene expression filter (FPKM > 1). To condense the
results even further, only the top ranked neoantigen was selected per variant across all alleles,
lengths, and registers (position of amino acid mutation within peptide sequence), resulting in
4,891 total neoantigens with an average of 16 neoantigens per case. This list was then
processed with pVACvector to determine the optimum arrangement of the predicted high
quality neoantigens for a DNA-vector based vaccine design (Figure 4.5).
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Figure 4.5: An example from pVACvector output showing the the optimum arrangement of
candidate neoantigens for a DNA-vector based vaccine design. The figure shows
visualization of a circularized DNA insert carrying the encoded neoantigenic peptide
sequences to be synthesized and encoded/cloned into a DNA plasmid. DNA sequences
encoding each peptide are ordered (with use of spacer sequences where needed) to ensure
there are no strong-binding junctional epitopes. Each neoantigenic peptide candidate is
shown in Blue,Green, Red, Orange, Purple, and Brown. Spacer sequences, where added for
minimizing junctional epitope affinity, are depicted in Black, along with the binding affinity
value
of
the
strongest
binding
junctional
epitope.
Labels
depict
MutantIdentifier:GeneName:TranscriptName:TranscriptNumber:TypeofMutation:AminoAcid
Change.

4.4.2 Comparison of epitope prediction software
Since we offer support for as many as eight different epitope prediction tools, we assessed
agreement between these algorithms from a random subset of 100,000 peptides (Figure 4.6).
The highest correlation was observed between the two stabilization matrix method (SMM)based algorithms - SMM and SMMPMBEC. The next best correlation was observed between
NetMHC and MHCflurry.
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Figure 4.6: Spearman Correlation between prediction values This figure shows a heatmap
of the Spearman correlation between binding affinity predictions from all eight algorithms
generated from random subsample set of size 100,000 peptides

keWe also evaluated if there were any biases within the algorithms to predict strong (i.e.
binding affinity < = 500nM) or weak binding epitopes (Figures 4.7 and 4.8). We found that
MHCnuggets predicts the highest number of strong-binding candidates alone. Of the total
number of strong binding candidates predicted, 64.7% of these candidates were predicted by
a single algorithm, 35.2% were predicted as strong-binders by two to seven algorithms, and
only 1.8% of the strong-binding candidates were predicted as strong binders by the
combination of all eight algorithms. Infact, even if one (or more) algorithms predict a peptide
to be a strong binder, often another algorithm not only doesn't agree but disagrees by a large
margin, in some cases predicting that same peptide as a very weak binder. This remarkable
lack of agreement underscores the potential value of considering multiple algorithms.
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(a)

(b)

Figure 4.7: Upset plot between number of peptides and prediction algorithms Intersection
of peptide sequences predicted by different algorithms are shown using upset plots. The yaxis shows the number of overlapping unique neoantigenic peptides predicted for each
combination of algorithm depicted on the x-axis. Each filled black circle shows the sets
contained in an exclusive intersection (i.e. the identity of each algorithm), while the light
gray circles represent the algorithm(s) that do not participate in this exclusive intersection.
(a) Upset plot for the top 20 algorithm combinations ranked by the number of peptides
predicted to be a good binder (mutant IC50 score < 500 nM). The combination of all eight
algorithms (highlighted orange) ranks the 8th highest; (b) Upset plot for algorithm
combinations where at least six algorithms agree on predicting a peptide to be a good binder
(MT IC50 score < 500 nM). The combination of all eight algorithms (highlighted orange)
ranks the highest.
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Figure 4.8: Number of peptides predicted to be good binders (MT IC50 Score < 500 nM)
versus number of algorithms used.
Next we determined if the number of human HLA alleles supported by these eight algorithms
differed. As shown (Figure 4.9), MHCnuggets supports the highest number of human HLA
alleles.
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(a)

(b)

(c )

Figure 4.9: Human HLA Allele subtype support distribution by eight algorithms (a)
Number of allele subtypes supported versus number of algorithms; (b) Upset plot for
algorithm combinations ranked by the number of allele subtypes supported by pVACseq.
Total number of HLA allele subtypes supported by pVACseq: 9,851. The combination of all
eight algorithms (highlighted orange) ranks the 3th highest; (C) Upset plot for algorithm
combinations ranked by the number of allele subtypes supported for the 300 TCGA samples
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analyzed in this study. Total number of HLA alleles across patient cohort: 130. The
combination of all eight algorithms (highlighted orange) ranks the 2nd highest.

4.4.3 Comparison of filtering criteria
Since pVACtools offers a multitude of ways to filter the list of predicted neoantigens, we
evaluated and compared the effect of each filter in narrowing down high quality neoantigen
candidates.

We first compared the effect of running pVACtools using the commonly used standard
binding score cutoff of <= 500nM (parameters: -b 500) versus the newly added allele-specific
score filter (parameters: -a). These cutoffs were, by default, applied to the “median” binding
score of all prediction algorithms. 96,235 neoantigens (average 320.78 per patient) were
predicted using the 500 nm binding score cutoff compared to 94,068 neoantigens (average
313.56 per patient) using allele-specific filters. About 79% neoantigens were shared between
the two sets.

We also narrowed further to include only those predictions where the default “median”
predicted binding affinities (< = 500 nm) are lower than each corresponding median wildtype
peptide affinity (parameters: -b 500 -c 1) (i.e. a binding affinity mutant/wild type ratio or
aggretopicity value indicating that the mutant version of the peptide is a stronger binder).
Using the aggretopicity value filter, 70,628 neoantigens (average 235.43 per patient) were
predicted versus the previously reported 96,235 neoantigens without this filter.

We also evaluated the effect of the aggretopicity value filter when applied to the set of
epitopes filtered on “lowest” binding score of < = 500 nm ( parameters: -b 500 -c 1 -m
lowest). This filter reports peptides where at least one of the algorithms predicts a strong
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binder, instead of calculating a median score and requiring that to meet the 500 nm threshold
(Figure 4.10). Using the lowest binding score filter resulted in an 11-fold increase in the
number of candidates predicted (827,423 candidates, average 2,758.08 per patient).

(a)

(b)

Figure 4.10: Overall of distribution of binding affinity scores (nM) for peptides where at
least one of the algorithms predicts a strong binder. HLA allele subtype-specific thresholds
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are applied when available, otherwise the default cutoff binding affinity of 500 nM is used.
Peptides with predicted MT IC50 scores lower than their respective cutoff scores are
highlighted in orange. The median MT IC50 scores of each algorithm’s prediction are
marked for reference. (a) Original data on logarithmic scale; (b) A ceiling of 1000 nM is
applied to the MT IC50 scores.

Using the median (default) binding affinity filtering criteria, we next applied coverage and
expression based filters. First, we filtered using the recommended defaults i.e. greater than
5X normal DNA coverage, less than 2% normal VAF, greater than 10X tumor RNA and
DNA coverage and greater than 25% tumor RNA and DNA VAF, along with FPKM > 1 for
transcript level expression (parameters: --normal-cov 5 --tdna-cov 10 --trna-cov 10 --normalvaf 0.02 --tdna-vaf 0.25 --trna-vaf 0.25 --expn-val 1). A total of 10,730 neoantigens were
shortlisted across all samples with an average of 35 neoantigens per case. We then compared
this set with a slightly more stringent criteria using tumor DNA and RNA VAF of 40%
(parameters: --tdna-vaf 0.40 --trna-vaf 0.40). This shortened our list of predicted neoantigens
to 4,073 candidates averaging to 13 candidates per patient.

Lastly, we applied our top binding score filter to select the best candidate neoantigen per
variant across all alleles and all lengths (one result per variant) using the previously described
default filters. This resulted in a final list of 4,891 neoantigens across 300 patients.

4.4.4 Demonstration of neoantigen analysis using pVACfuse
To demonstrate the potential of neoantigens resulting from gene fusions, we analyzed TCGA
prostate cancer RNA-seq data from 302 patients. This dataset was used as a demonstration set
for the neoantigen prediction supported by Integrate-Neo. We wanted to assess the difference
(if any) in neoantigens candidates reported by INTEGRATE-Neo139 using the one MHC
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Class I prediction algorithm it supports (NetMHC) versus an ensemble of eight Class I
prediction algorithms supported in pVACfuse.

Using 1,619 gene fusions across 302 samples as input, pVACfuse reported 2,104 strong
binding neoantigens (binding affinity <= 500nM) resulting from 739 gene fusions. On
average, there were about 7 neoantigens per sample resulting from an average of 2 fusions
per case. This is an eight fold increase in the number of strong binding neoantigens predicted
by pVACfuse versus the ones reported by INTEGRATE-Neo, which reported 261
neoantigens across 210 fusions.

4.5 Conclusion
As reported from our demonstration analysis, a typical tumor has too many possible
neoantigen candidates to be practical for a vaccine. There is therefore a critical need for a tool
that takes in the input from a standard sequencing analysis pipeline and reports a filtered and
prioritized list of neoantigens. pVACtools enables a streamlined, accurate and user-friendly
analysis of neoantigenic peptides from NGS cancer datasets. This suite offers a complete and
easily configurable end-to-end analysis, starting from somatic variants and gene fusions
(pVACseq and pVACfuse respectively), through filtering, prioritization, and visualization of
candidates (pVACviz), and determining the best arrangement of candidates for a DNA vector
vaccine (pVACvector). Furthermore, by supporting additional classes of variants as well as
gene fusions, we offer an increase in the number of predicted epitopes which is even more
important in the case of low mutational burden tumors. Finally, by extending support for
multiple binding prediction algorithms, we allow for a consensus approach. The need for this
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integrated approach is made abundantly clear by the high disagreement between these
algorithms observed in our demonstration analyses.

The results from pVACtools analyses are already being used in cancer immunology studies,
including studying the relationship between tumor mutation burden and neoantigen load to
predict response in checkpoint blockade therapy trials and the design of cancer vaccines in
ongoing clinical trials. We anticipate that pVACtools will make such analyses more robust,
reproducible, and facile as these efforts continue.

4.6 Data availability
Data from 100 cases each of melanoma, hepatocellular carcinoma and lung squamous cell
carcinoma were obtained from TCGA and downloaded via the Genomics Data Commons
(GDC). This data can be accessed under dbGaP study accession phs000178. Data for
demonstration and analysis of fusion neoantigens was downloaded from the Github repo for
Integrate (https://github.com/ChrisMaherLab/INTEGRATE-Vis/tree/master/example).

4.7 Software availability
The

pVACtools

codebase

is

hosted

publicly

on

GitHub

at

https://github.com/griffithlab/pVACtools and https://github.com/griffithlab/BGA-interfaceprojects (pVACviz). User documentation is available at pvactools.org. This project is
licensed under the Non-Profit Open Software License version 3.0 (NPOSL-3.0,
https://opensource.org/licenses/NPOSL-3.0). pVACtools has been packaged and uploaded to
PyPi under the “pvactools” package name and can be installed on Linux systems by running
the `pip install pvactools[API]` command. Installation requires a Python 3.5 environment
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which can be emulated by using Conda. Versioned Docker images are available on
DockerHub (https://hub.docker.com/r/griffithlab/pvactools/).
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Chapter 5: Conclusion and future
directions
Neoantigen prediction accuracy is a critical factor in the widespread adoption of cancer
vaccine-based immunotherapy, as vaccine efficacy depends on selection of the best
neoantigens. The approaches developed in this work should help to identify, evaluate and
characterize tumor-specific neoantigens in a much-reduced time, thereby increasing the
applicability of cancer vaccines for clinical use.

Preliminary studies in human patients have shown that only a subset of candidate antigens
predicted by existing methods elicit an immune response when administered as a vaccine72.
In fact, only about 16–43% of the predicted neoantigenic peptides included in a vaccine
formulation for any reported clinical trial to-date yield a CD8+ T cell response. This lack of
accuracy in prediction may emerge from several sources of uncertainty in neoantigen
prediction, including the inability to identify which of the predicted neoantigenic peptides
with high binding affinity will be processed and presented to the immune system by the
MHC. This aspect is not readily predicted computationally, although there are several
algorithms available to perform these predictions
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. Hence, there is a critical need for an

approach that learns from the response data obtained from clinical cancer vaccine trials and
uses the information to refine neoantigen predictions for future trials. We have hypothesized
that a machine learning approach might help in refining these predictions such that a higher
percentage of the neoantigens are able to induce T-cell immunity when administered in the
cancer vaccine. Hence, we have initiated an effort to curate these data from multiple clinical
trials and to implement a machine learning-based approach.
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Pursuit of machine learning will require several components, outlined below:
Construct target variable(s)
To assess ‘good’ vaccine candidates, we will first need to define appropriate criteria to
construct a target variable(s) as an indicator of immunogenicity. Different immunology labs
may use different metrics for such an analysis, and since not all labs actively use neoantigens
for vaccination per se, some data mining will be required to determine which assays are used
routinely. This will help in narrowing down a common endpoint across different projects to
assess immunogenicity. Some examples of these assays include ELISPOT/ELISA that
measures IFNγ production, Peptide–MHC tetramers/dextramer assays, or a combination of
both.

Obtain data from published and ongoing research
There are several in-house vaccine clinical trials currently underway as collaborations
between the McDonnell Genome Institute and the Siteman Cancer Center. For example, the
Komen Promise Vaccine trial which aims to design and treat triple negative breast cancer
patients during the window of opportunity following neoadjuvant chemotherapy, surgery and
radiation therapy, is a

phase I clinical trial that compares synthetic polypeptide-

(https://clinicaltrials.gov/ct2/show/NCT02427581)

to

DNA-based

vaccines

(https://clinicaltrials.gov/ct2/show/NCT02348320). Initial results were already published for
a

first-in-human

vaccine

trial

in

melanoma

patients

(https://clinicaltrials.gov/ct2/show/NCT00683670). There were five patients enrolled in this
phase 1 vaccine clinical trial employing autologous, functionally mature, interleukin (IL)12p70-producing dendritic cells (DC) carrying neoantigens identified by our pipeline.
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We also are actively curating previously published research to inform our machine learning
approach37,41,42,66,156,157. One caveat for these published datasets is the absence of
transcriptome data in some cases, which will need to be imputed while building the predictive
model.

Engineer features based on dataset properties
Since genomic and/or transcriptomic data are now used routinely for assessment of
neoantigens, it is essential to use this information from such massively parallel sequencing
studies to select appropriate features for building the machine learning classifier. We may use
basic aggregators on the given data to engineer meaningful features for the model. Some of
these features include:
a)

Tumor coverage from DNA and/or RNA

b)

Tumor variant allele fraction from DNA and/or RNA

c)

Gene expression: this may be in the form of FPKM values obtained from RNA-(Cap)

Seq data or quantitative expression from qPCR.
d)

Binding affinity from epitope prediction algorithms

e)

Fold change in the predicted binding of the mutant epitope versus the wildtype

Additional features such as HLA-type, type of amino acids in the peptide, properties of amino
acids (hydrophobic, hydrophilic, polar), position of the mutation in the peptide sequence
(anchor residues, TCR-facing residues) etc. could also be investigated.

Select feature subset
Since there are several different features associated with sequencing datasets, it may be
possible that not all features are relevant when building a predictor. Popular feature selection
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methods such as chi squared and analysis of variance (ANOVA) could be used to retrieve a
subset of features that have a strong correlation with the target variable. This subset would be
used by the predictive model to carry out the classification.

Perform predictive modeling
Once a set of features is finalized, a feature matrix is constructed based on the features
selected for the study as well the target variable. A predictive model would then be developed
which would use the feature matrix as input to predict the best set of neoantigens to be used
for analysis and/or vaccination. There are several different machine learning approaches that
can be evaluated including neural networks, random forest, support vector machine and deep
learning approaches. Evaluation is generally done by cross validation techniques such as N-fold cross validation, leave one out cross validation, etc. Various metrics like area under the
ROC curve (AUC), accuracy of the model, precision, recall, F1 score, etc. can be used to
determine the appropriate classifier.

As we learn from ongoing early human trials, the methods developed in this thesis will help
in identification, selection and characterization of high quality neoantigens from different
cancer sequencing datasets. Furthermore, these methods could be directly applied to assist in
development of immunotherapy based clinical trials and basic immunology studies such as
studying the relationship between tumor mutation burden and neoantigen load to predict
response in checkpoint blockade therapy trials and the design of personalized cancer
vaccines. The computational framework developed in this work (pVACtools) will help
optimize the composition of personalized cancer vaccines with high precision that will hasten
vaccine design to enable growing clinical demand. Additionally, as mentioned previously,
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these methods could even be extended by incorporating the feedback from the growing
number of trials to improve the prediction of neoantigens and their immunogenicity.
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